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Abstract 
Asthma is a common and complex inflammatory disease of the airways 
characterized by deregulated immune responses that involves activation of 
multiple cell types including Th2 cells, IgE producing B cells, mast cells, 
basophils and eosinophils as well as resident lung cells such as epithelial, 
smooth muscle cells and macrophages. Despite intensive research, there are 
still unmet needs in the treatment of asthma. Recently, a new cytokine of IL-1 
family, named IL-33 emerged as a potentially important factor in the 
immunopathogenesis of allergy and asthma. It was recently shown in our 
laboratory that intranasal administration of IL-33 can induce certain 
physiological features that are characteristic of experimental asthma, such as 
eosinophilic inflammation, Th2 cytokine and antibody production as well as 
increased airway hyperresponsiveness. 
The effect of IL-33 on the activation and differentiation of allergen specific Th2 
cells has been well studied. However, the contribution of IL-33 to the activation 
of lung resident and inflammatory innate cells remains undefined. In this 
project I focused on alveolar macrophages and eosinophils as both cell types 
were reported to express IL-33R, ST2L and are thought to play a crucial role in 
asthma pathogenesis. 
I raised the hypothesis that IL-33 released locally in the lungs may trigger 
symptoms resembling asthma through the activation of airway alveolar 
macrophages. Furthermore, I hypothesize that IL-33 may exacerbate and 
maintain inflammation in the lungs by the direct activation of eosinophils.  
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In our previous study we showed that IL-33 could switch the quiescent 
phenotype of alveolar macrophages toward the alternatively activated 
phenotype (M2, AAM). In the first part of my thesis I looked at the 
consequences of this phenomenon for airway inflammation. Using clodronate 
liposomes in vivo I was able to eliminate macrophage population from the lungs 
and demonstrated that resident alveolar macrophages are crucial for the 
development of IL-33-induced eosinophilic inflammation in the airways. I then 
examined the contribution of IL-13, a known M2 differentiation factor, to airway 
inflammation. Using anti-IL-13 neutralizing antibodies I showed that IL-13 is 
required for the IL-33-triggered differentiation of alveolar macrophages toward 
M2 phenotype as well as for eosinophilic inflammation. 
Next, I looked at how IL-33/ST2 pathway modulates the differentiation and 
activation of eosinophil. I demonstrated that bone marrow hematopoietic 
progenitors CD117+ express ST2L and that IL-33 is able to differentiate these 
cells toward eosinophils. By employing deficient mice or neutralizing antibodies 
I found that this process is ST2 and IL-5 dependent and independent of IL-13. 
I then extended my research interests to include mature mouse and human 
eosinophils. I showed that both human and mouse resting eosinophils express 
low levels of ST2L which can be markedly increased by IL-33. Moreover, I 
demonstrated that eosinophils that are recruited to the lungs during 
experimental allergic airway inflammation express high levels of ST2L. 
Furthermore, I carried out a study on effector function of eosinophils. I found 
that IL-33 induces IL-13, IL-6 and increases TARC, TGF-β production by mouse 
eosinophils. In addition, IL-33 exacerbated IgG-induced human and mouse 
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eosinophil degranulation, likely by enhancing FcγRII expression. Having shown 
earlier that IL-13 is requited for the polarization of alveolar macrophages 
toward AAM by IL-33 in vitro and in light of the fact that IL-33-stimulated 
eosinophils can be a significant source of IL-13; I went on to investigate the 
interaction between macrophages and eosinophils. Using co-cultures of ST2-/- 
macrophages with WT eosinophils in Transwell system, I demonstrated that 
IL-33- but not IL-5-activated eosinophils can support macrophage polarization 
toward the pro-inflammatory AAM phenotype, partially through the production 
of IL-13. 
Finally, given the role of IL-33/ST2L axis in eosinophil activation in vitro, I 
investigated the contribution of IL-33-activated eosinophils to airway 
inflammation in vivo. Using adoptive transfer protocol I showed that the 
contribution of IL-33-activated eosinophils to airway inflammation is mediated 
primarily by the release of cytokines from these cells which, in turn, recruits 
other inflammatory cells and supports the differentiation of alveolar 
macrophages towards AAM. 
These data show that IL-33/ST2 pathway regulates multiple features of alveolar 
macrophage and eosinophil biology that can have a significant impact on 
asthma pathophysiology in the airways. Studies carried out in our laboratory 
and elsewhere suggest that IL-33 is equally capable of activating other cell 
types that have been implicated in asthma pathology such as Th2, B1 cells, 
DCs, mast cells and basophils. Therefore, targeting IL-33/ST2 pathway may 
potentially offer a promising therapeutic approach to asthma and allergy.  
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1.1. Interleukin-33 
A cytokine interleukin-33 (IL-33, IL-1F11) as it is now called, was initially 
reported as a clone DVS27 gene product, highly upregulated in canine 
vasospastic cerebral arteries after subarachnoid hemorrhage (2). Then, in 2003, 
the same sequence was described as a nuclear factor present in endothelial 
cells of high endothelial venules (HEVs) of secondary lymphoid organs 
(HEVECs), namely human lymph nodes, tonsils and Peyers's patches and 
referred to as NF-HEV (3). However, apart from the suggestion by the authors, 
that NF-HEV can help controlling the specialized HEV phenotype there was a 
paucity of data on the role of the protein. 
In 2005 Schmitz and colleagues used a molecular profile based on the 
properties of already known IL-1 cytokine family members to search genetic 
sequence databases (4). They established that NF-HEV molecule was in fact a 
member of IL-1 cytokine superfamily and shared many molecular properties 
with several closely related cytokines, such as IL-1α/β (IL-1F1/IL-1F2), IL-1Ra 
(IL-1F3), and IL-18 (IL-1F4). As a newly identified member of IL-1-like 
cytokines, NF-HEV was renamed to IL-33 (IL-1F11) . 
1.1.1. Structure and molecular properties of IL-33 
Schmitz et al. matched IL-33 to its specific receptor, a protein known as orphan 
receptor T1/ST2 (IL-33Rα) which will be discussed in detail in a separate 
chapter (4). These authors found the human IL-33 gene to be located on 
chromosome 9 in 9p24.1 region, while its murine counterpart was mapped to 
chromosome 19qC1 region. The lengths of IL-33-encoding cDNA sequences are 
 22 
similar: in humans a full length IL-33 protein (pro-IL33) of 30 kDa molecular 
mass is constituted by 270 amino-acids while its murine counterpart is 266 
amino-acid in length and forms a 29.9 kDa protein. At the amino acid level the 
two proteins share 55% of the sequence. Moreover, by aligning amino acid 
sequences of human and murine mature IL-33 with members of the IL-1 family, 
Schmitz and colleagues demonstrated that both IL-33 proteins share 
12 β strands that make up the characteristic β-trefoil fold, a structure first 
described in IL-1 by Priestle et al (5). Phylogenetic tree analysis revealed that 
among other known IL-1 family members IL-33 is most closely related to IL-18 
(IL-1F4). In contrast to other family members neither of the two cytokines is 
linked to the IL-1 gene cluster on human chromosome 2. 
The structure of IL-33 suggests that it has the capacity to act both as a 
cytokine and as a nuclear factor. Indeed, unlike most other members of the 
IL-1 family of cytokines, with one exception for IL-1α, IL-33 is often found in 
the nucleus rather than cytoplasm (3, 6-7). In humans, it is commonly localized 
in nuclei of epithelial and endothelial cells (3, 6, 8) while in mouse it has also 
been shown to have affinity for chromatin of bone marrow-derived mast cells 
in vitro (9). Its nuclear localization is mediated by a nuclear localization signal in 
its N’-terminus (NLS), while chromatin binding capabilities are facilitated by a 
homeodomain (helix-turn-helix-like motif) (10-11), which presents close 
homology to LANA (latency-associated nuclear antigen), a protein coded by 
Kaposi’s sarcoma-associated herpesvirus (11). The other portion of IL-33 
protein at the carboxyl terminus is a cytokine domain formed by 12 βstrands as 
mentioned above, called the IL-1-like domain. Apart from the fact that IL-33 
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can bind to the acidic residues of a dimeric histone (H2A-H2B) thereby 
suppressing gene transcription in vitro, the role for IL-33 as a nuclear factor 
remains obscure (11). 
1.1.2. IL-33 processing 
Similar to other members of IL-1 family, such as IL-18 and IL-1β, IL-33 lacks 
signal peptide at the N’ terminus that is required for a successful assembly via 
the endoplasmic reticulum and transport through the Golgi apparatus (4). 
However, despite early predictions IL-33 differs considerably from the two 
cytokines in the way that it is cleaved by proteases. Although in vitro studies 
showed that IL-33 can be processed by caspase-1 from pro-IL-33 30 kDa down 
to what was originally assumed to be an active mature form of 20-22kDa, the 
reaction is rather inefficient, when compared with the cleavage of IL-1β (12-
14), and does not occur in the environment devoid of other proteases (14). 
Even when cells were modified by introducing mutations carrying a potential 
caspase-1 binding site for the IL-33 to be expressed, the 30kDa pre-IL-33 was 
still dominant. However, studies by other groups showed that the cleavage 
could be prevented by using a specific caspase-1 inhibitor (4, 12). It was 
suggested that the activation of the NLRP3-inflammasome with alum adjuvant 
in vivo activates caspase-1 which, in turn, cleaves pro-IL-33 allowing for its 
secretion (15). The mature form of IL-33 can also be produced by 
calpain-mediated cleavage (16). Interestingly, experiments showed that 
proteases that are activated during cell apoptosis, such as caspase-7 and 
caspase-3 could do the cleavage (12-13, 17). These apparently conflicting data 
may be partially explained by the observation that pro-IL-33 lacks a classical 
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caspase-1 binding site (Derek Gilchrist, unpublished data). Instead, it contains 
cleavage sites for caspase-7 and caspase-3 are located within its IL-1-like 
domain (cytokine domain). Therefore it is possible that pro-IL-33 is not a 
primary target for caspase-1. Rather, the protein is actually processed by other 
proteases that are controlled by caspase-1. The important point is that the 
maturation process facilitated by caspases renders the IL-33 biologically 
inactive. 
1.1.3. Secretion of IL-33 
There are limited and inconclusive data available about how IL-33 is released. It 
was shown that IL-33 is released by human acute monocytic leukemia cell line 
(THP-1) upon stimulation with alum adjuvant, lypopolysaccharide (LPS), LPS 
with alum, or upon infection with Listeria moncytogenes and Salmonella 
typhimurium (14-15). Stimulation with a known cell activator PMA (phorbol 
12-myristate 13-acetate) was reported to induce IL-33 secretion from rat 
cardiac fibroblasts (18). Supporting data was also obtained in mixed murine 
glial cells cultured in the presence of LPS and ATP (19).  
Recently, an alternative mechanism for IL-33 release through cell necrosis has 
been proposed that takes into account the indirect nature of IL-33 processing 
by caspases as well as the primarily nuclear localization of a full-length protein 
in vivo (6, 10). This notion stems from the observation that IL-33 harbours 
structural elements very similar to those found in IL-1α and so-called 
high mobility group box 1 (HMGB1). The latter is a nuclear factor with 
transcription-suppressing capabilities commonly found in the nucleus and is 
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only released through cell necrosis when it contributes locally to the 
inflammatory processes at sites of tissue damage (20-22). Although HMGB1 is 
effectively acting as a potential danger signal associated with tissue damage, it 
is rendered inactive by the caspase-dependent processes associated with 
apoptosis (23). In this case it contributes to the apoptotic cell-mediated 
tolerance. The necrosis-associated mechanism of IL-33 release is consistent 
with its postulated role as a novel ‘alarmin’. By definition, alarmins are 
extra-cellular mediators that serve as an endogenous, ‘danger signal’, designed 
to be released immediately upon and as a direct result of tissue damage or 
pathogens breaching the epithelial barriers. It is possible that IL-33 may be part 
of such warning system by complementing signals from so-called 
pathogen-associated molecular pattern receptors (PAMPs), such as TLR family, 
or NOD-like receptor protein family (nucleotide-binding oligomerization domain 
(24-25). If so, the release mechanism through cell necrosis may actually be the 
primary one, while the caspase-dependent mechanism, which renders mature 
IL-33 biologically inactive (12-13) may be used during steady state tissue 
turnover where there is no need for triggering inflammation and mounting a 
defence response. 
Taken together, it seems that the truncated form of IL-33 is inactive as a 
cytokine and released during apoptosis, while the immature (proIL-33) form of 
the protein is released during cell necrosis and may act as an endogenous 
‘alarmin’. 
 26 
1.1.4. Expression pattern of IL-33 in homeostasis and disease 
The list of cellular sources of IL-33 seems to be consistent with the proposed 
role of IL-33 as an alarmin. The cytokine is predominantly expressed in 
structural lining cells that act as a primary defence mechanism against invading 
pathogens. IL-33 can be found across the vascular system, particularly in 
endothelial cells of high endothelial venules (HEV cells), but also in large and 
small vessel endothelial cells, including liver, colon, small intestine, stomach, 
kidney, prostate, skin and skeletal muscles (6, 8) where it is commonly mapped 
to the nucleus. Another common location for IL-33 protein is the epithelial cells 
of many organs, including stomach, tonsilar crypts, salivary glands, skin, and 
lung tissue (6, 26). IL-33 protein expression can be markedly elevated 
compared to steady state at several locations under pathologic conditions which 
includes lung epithelial cells and smooth muscle cells of asthmatic patients (26-
28), skin from atopic dermatitis patients (29), brain of Alzheimer’s disease 
patients, pancreatic myofibroblasts of chronic pancreatatis patients (30), colon 
of ulcerative colitis patients (31), and synovium of rheumatoid arthritis (RA) 
patients (6-7, 32). In inflammatory arthritis model, TNF-α and IL-1β are 
thought to be responsible for IL-33 upregulation (7). 
Although full-length, nuclear IL-33 protein was found constitutively expressed in 
resting blood vessel endothelium, the expression is rapidly down-regulated on 
the onset of tumor- or wound healing-associated angiogenesis, compared to 
vessels in healthy tissue. Some in vitro experiments strongly suggest that 
nuclear IL-33 expression can only occur during cell cycle arrest. However, the 
non-proliferatory status alone was not sufficient to restore the level of nuclear 
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IL-33 that could be detected by immunohistochemistry. This required an 
additional cell contact inhibition signal that in vivo may come from spatial 
restrictions in densely packed endothelial cells of healthy vasculature. Similar 
cell-to-cell signal could be generated in super-confluent endothelial cell 
monolayers in vitro, as shown in HUVEC cultures. Consistently, nuclear IL-33 
was scarcely detectable (or not at all) in immature blood vessels of human 
tumours which are highly angiogenic (8). In contrast, another study concluded 
that long, immature form of nuclear IL-33 protein is abundant in many human 
tumours, as well as in normal tissues, making it suitable for use as a general 
nuclear marker of endothelial cells (6). This apparent discrepancy still awaits to 
be explained as tumour tissues, owing to their high proliferation status, tend to 
become hypoxic which, on its own, should enhance nuclear IL-33 expression 
(Neal Millar, personal communication), unless the inhibition caused by VEGF can 
counteract the effect of hypoxia. Interestingly, as a cytokine, IL-33 induces 
both angiogenesis and vaso-permeability, which is similar to what VEGF does. 
Furthermore, IL-33 increases the endothelial cell proliferation, migration, and 
tubular network formation comparable with VEGF in vitro. Consistently, IL-33 
promoted vessel sprouting and neovascularization in mice in vivo, as well as the 
proliferation, migration, and morphologic differentiation of human endothelial 
cells in vitro, apparently by stimulating endothelial NO production (33). Given 
the distinct roles of nuclear and released forms of other cytokines, such as IL-1, 
similar effect may occur in endothelial cells expressing IL-33. However, the 
precise contribution of both forms of IL-33 to the regulation of angiogenesis 
and homeostatic tissue turnover awaits further clarification. 
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In terms of IL-33 expression on transcriptional level, IL-33 mRNA is ubiquitously 
expressed across many tissues and can be detected virtually at any location in 
human and murine systems. To date, the only major organ in which IL-33 
mRNA was not detected is human spleen, although IL-33 message was found in 
mouse spleen tissue (4), as well as in mouse splenic dendritic cells upon 
stimulation with LPS. 
1.1.5. IL-33 signaling via ST2L and IL-1RAcP complex 
In 2005 Schmitz et al. (4) identified that so called “orphan receptor”, T1/ST2 
(or IL-1R4, now also called IL-33Rα), a molecule known for sixteen years, is a 
receptor for IL-33 (IL-1F11). This was soon supplemented by the observation 
that another molecule, IL-1R accessory protein (IL-1RAcP), is required in the 
formation of a fully functional IL-33 receptor complex (34-35). In fact, IL-1RAcP 
is widely shared between several other IL-1-related cytokines, namely IL-1α 
(IL-1F1), IL-1β (IL-1F2), IL-1F6, IL-1F8 and ILF-9, to form heterodimer 
receptor complexes with the respective alpha chains that assure single-cytokine 
specificity of the receptor complexes they constitute. The expression of ST2 
gene can produce two major splice variants of ST2 mRNA, the membrane 
bound form, ST2L, and truncated soluble form, sST2. Each splice variant is 
controlled by a pair of distinct promoters (36). Also, alternate splicing variants 
(ST2LV and sST2V) were reported in humans and chickens (37-38). The 
membrane-bound ST2L is required for mediating IL-33 signaling, whereas 
soluble sST2 acts as a decoy receptor by masking IL-33 biologic activity (39-40) 
in a similar fashion that soluble IL-1R does to IL-1 signaling. IL-33 binds 
specifically to ST2L and does not cross-react with any other IL-1R related 
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receptors (4, 41-42). Both ST2L and IL-1RAcP are necessary for IL-33 action as 
mice deficient either for IL-1RAcP or ST2 are completely unresponsive to IL-33 
administration while wild type animals exhibit a marked inflammatory reaction 
(35, 43). Consistently, it was demonstrated that soluble IL-1RAcP enhances the 
ability of soluble ST2 to inhibit IL-33 signaling (42). 
Several recent studies demonstrated that IL-33-generated signal can also be 
regulated through the binding of IL-33 to an alternate receptor complex that 
consists of ST2L and so called single Ig IL-1-related molecule (SIGIRR), also 
referred to as Toll IL-1R8 (TIR8) (44). This molecule has been implicated to be 
a negative regulator of Toll-like receptor (TLR)- and IL-1R-mediated immune 
responses (45). SIGIRR-deficient dendritic cells exhibit increased 
responsiveness to the stimulation with TLR ligands as well as IL-1 and IL-18 
(46) and SIGIRR-deficient Th2 cells showed a more abundant expression of 
Th2-associated cytokines in response to IL-33 (44). These data suggest that 
SIGIRR/ST2L receptor complex may function as a negative regulator of IL-33, 
similarly to sST2 decoy receptor. 
The membrane bound IL-33 receptor, ST2L contains common intercellular 
domain called Toll-IL-1R (TIR) domain, which is shared among the entire 
TLR/IL-1R receptor superfamily. It was demonstrated that TIR domain of 
IL-1RAcP directly interacts with the TIR domain of ST2L/IL-33 and contributes 
to facilitating the IL-33-mediated signal (35). Downstream of the 
IL-33/ST2L/IL-1RAcP complex, IL-33 signal is passed on by several adapter 
molecules, most of which being commonly used by other members of IL-1R 
family. Schmitz et al. showed that IL-33 binding triggers the recruitment of the 
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myeloid differentiation primary-response protein 88 (MyD88), and TNF 
receptor-associated factor (TRAF6) to TIR domain in the cytoplasmic portion of 
ST2L (and IL-1RAcP) where the molecules are activated (4). The involvement of 
protein MyD88 adaptor, but not TRIF, was found indispensable for ST2L/IL-33 
signaling, both in vitro (43, 47) and in vivo (48). Downstream of 
TIR/MyD88/TRAF6 interactions, a cascade of phosphorylation includes 
IL-1R-associated kinase 1 (IRAK1) and IRAK4, which eventually leads to the 
activation of all three mitogen-activated protein kinases (MAP kinases) and a 
transcription factor called nuclear factor-κB (NF-κB) in T cells and mast cells (4, 
43). Consistently, Schmitz et al. demonstrated that Erk1/2, p38 and NF-κB 
activation can be blocked in the presence of anti-ST2 antibody in vitro (4). 
Furthermore, the detailed analysis of IL-33-induced mast cell activation 
revealed that IL-33 triggers NF-κB phosphorylation by intracellular calcium 
mobilization mediated by phospholipase D and sphingosine kinase 1 (29). 
As mentioned above, IL-33 can also signal entirely independent of Ca2+ in 
which case a phosphorylation cascade of MAP kinases is triggered, including 
Erk1/2, p38 and JNK, that results in the activation of transcription factor called 
activator protein 1 (AP-1) (4, 29, 43). Interestingly the IL-33-induced activation 
of p38, JNK and NF-κB depends on TRAF6 phosphorylation, while ERK can be 
activated in a TRAF6-independent fashion as demonstrated in mouse embryonic 
fibroblasts (MEFs) (49). Both pathways (NF-κB and MAP kinases) can be 
regarded as complementary to one another in a sense that each facilitates 
some of the responses, but not the others. For example, in T cells IL-33 
mediates the production of IL-5 and IL-13 via different mechanisms: whereas 
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the IL-33-induced IL-5 expression could be suppressed by specific inhibitors of 
p38, ERK1/2 and JNK1/2 but not the inhibitor of NF-κB, the expression of IL-13 
was suppressed by p38, NF-κB and, to a lesser extent, by ERK1/2 and JNK1/2 
inhibitors. Also, it was recently shown that IL-33 mediated the production of 
IL-1β, IL-3, IL-6, TNF-α, MIP-1α (CCL3), MIP-2α (CXCL2), MCP-1 (CCL2), 
prostaglandin D2 leukotriene B4, and triggered degranulation in IgE-primed 
human and murine mast cells in an NF-κB-dependent manner. In contrast, the 
production of IL-5, IL-13, Eotaxin-2 (CCL24), RANTES (CCL5) and TARC 
(CCL17) was mediated by MAPK pathway and was essentially 
NF-κB-independent (29). 
1.1.6.  The role of IL-33 in type 1 immune responses 
1.1.6.1. Rheumatoid arthritis 
Based on the postulated role for IL-33 as a novel alarmin, one can predict that 
the levels of IL-33 are likely to be elevated at sites of high burden of cell death 
and that its function may be modulated by local milieu of cellular mediators. 
Indeed, elevated levels of IL-33 have been reported in patients with 
Th1/Th17-driven autoimmune diseases (7, 50). IL-33 and its receptor have 
been specifically mapped to disease-affected tissues - synovial fluid (51) and 
synovium of RA (7) and in skin lesions of psoriatic patients (52). In vitro 
analysis points at synovial fibroblasts as a possible source of IL-33 in RA 
synovium as they markedly up-regulate IL-33 expression upon TNF-α or IL-1β 
stimulation, both of which are hallmark cytokines in the immunopathogenesis of 
RA (7). Further evidence for the stromal expression of IL-33 comes from hTNF 
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transgenic mice that show abundant IL-33 expression in the bone and 
cartilage-invading synovium (Dr M. Kurowska-Stolarska, personal 
communication). Studies on ST2 deficient mice revealed that IL-33/ST2 
pathway is required for the development of both cellular and humoral 
autoimmunity as well as chronic articular inflammation in arthritis. ST2 deficient 
mice developed significantly attenuated collagen induced arthritis manifested by 
lower incidence and severity score. This was associated with lower levels of 
collagen-specific antibodies detected in sera and inhibited production of 
pro-inflammatory cytokines such as IFN-γ, IL-17 and TNF-α by draining lymph 
node cells and by articular tissue. A study on the mechanism behind this 
process revealed that IL-33-triggered, mast cell-derived IL-1 and IL-6 are 
responsible for shifting the balance of T cell response toward pathogenic Th17 
and Th1 (7). 
1.1.6.2.  Atherosclerosis and obesity 
Recently, IL-33/ST2 has been identified as a crucial pathway in adipose tissue 
biology. This is especially interesting in light of a current hypothesis that links 
adipose tissue immune status to glucose homeostasis. It is believed that 
adipose tissue infiltration by Th1 cells and pro-inflammatory macrophages (also 
known as M1) results in obesity and obesity-induced metabolic damage. 
Conversely, Th2- and Treg-derived cytokines and, most importantly, the 
alternatively activated macrophages (AAM, also known as M2 macrophages) are 
protective factors against obesity and type 2 diabetes (53). It was found that 
IL-33 is expressed in human adipose tissue predominantly in adipocytes and 
pre-adipocytes (54). Furthermore, IL-33R is expressed by adipose tissue 
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macrophages and adipocytes themselves (55). Mature mice deficient in ST2 
have an enhanced weight gain and more adipose tissue compared to WT mice 
while on a high fat diet suggesting that the endogenous IL-33/ST2 pathway 
plays a beneficial role in glucose homeostasis. Ex vivo treatment of epididymal 
stromal vascular fraction (eSVF) containing pre-adipocytes with IL-33 caused 
the inhibition of lipid accumulation that was associated with reduced expression 
of genes linked to lipid metabolism and adipogenesis. Most importantly, IL-33 
decreased the expression of resistin a mediator that is responsible for 
development of insulin resistance and type 2 diabetes. Administration of IL-33 
has a protective effect on body composition and glucose homeostasis by 
decreasing body fat, adipocytes size and total serum cholesterol. Obesity is also 
an independent risk factor for the development of chronic inflammation of 
arterial wall (atherosclerosis) which can eventually cause myocardial infraction 
and stroke. The development of atherosclerosis involves a complex interaction 
between vascular endothelium, serum lipids, inflammatory macrophages, 
Th1 cells, platelets and vascular smooth muscle cells (56). Recently, it has been 
found that the IL-33/ST2 pathway, in addition to being protective against 
adipose tissue inflammation, also protects against atherosclerosis. IL-33 is 
expressed in normal and atherosclerotic vasculature of mice deficient in ApoE, a 
protein essential for the transport and metabolism of lipids. Administration of 
IL-33 to ApoE-/- mice on a high fat diet reduced the size of the atherosclerotic 
lesion. The underlying mechanism of this protective effect of IL-33 against 
atherosclerosis and obesity is the ability of IL-33 to trigger type 2 immune 
responses such as Th2 cytokine production and AAM (M2) macrophage 
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differentiation as originally reported by Kurowska-Stolarska et al (26) and 
described in detail in chapter 1.2.2. 
1.1.7. The role of IL-33 in type 2 immune responses 
1.1.7.1.  Asthma and murine airway inflammation models 
Asthma is a complex and heterogeneous disease which is characterized by 
chronic inflammation of the airways associated with variable airflow obstruction 
arising from various genetic and environmental factors (57-58). The disease 
stems from an individuals hyper-response to innocuous environmental antigens 
that with time may lead to marked histlogical changes that can compromise 
lung function. This disproportional immune response to allergens is mediated by 
CD4+ T helper 2 cells, eosinophils, mast cells, neutrophils, macrophages, and 
IgE antibodies. The pathophysiology of asthma includes mucus hyper-secretion, 
bronchial hyper-responsiveness and smooth muscle hypertrophy and thickening 
of the epithelial basement membrane (57, 59). 
There are several lines of evidence that IL-33 is an important effector cytokine 
in asthma and allergy. IL-33 is expressed more abundantly in asthma patients 
compared to healthy individuals, which could be detected systemically in sera 
from affected individuals (60). However, the primary source tissue is thought to 
be the lung epithelial cells (26) and smooth muscle cells (27) which, owing to 
their localization in pulmonary mucosal barrier, may readily respond to a variety 
of environmental stimuli. Recently, Genome-Wide Association Studies (GWAS) 
identified several single nucleotide polymorphisms (SNPs) within IL-33 and ST2 
coding genes that are more frequent in asthma sufferers compared to healthy 
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subjects. These findings may represent the first step toward understanding the 
genetic mechanisms responsible for allergy and asthma (61-63). Moreover, in 
the ovalbumin (OVA)-induced murine asthma model of airway inflammation the 
levels of both soluble ST2 and IL-33 mRNA are markedly elevated in sera and 
lung tissues respectively (41, 43, 64). In addition, the administration of 
exogenous IL-33 into lungs, leads to asthma-like phenotype (43, 48). 
Numerous in vivo studies allowed for a fairly detailed investigation into the role 
of ST2/IL-33 pathway in allergy and asthma pathology. Those which used 
ST2-deficient animals demonstrate that permanent lack of IL-33 signaling can 
markedly attenuate key inflammatory responses such as BAL fluid eosinophilia, 
macrophage count and levels of IL-5, Eotaxins (CL11 and CCL24) and TARC 
(CCL17), together with pulmonary inflammation, while BAL fluid expression of 
IL-4 and IL-13 did not change, compared to BALB/c mice (26, 43). Serum IgG1 
and IgE levels were also normal (43). This outcome was reproducibly obtained 
in so-called acute airway inflammation model with a single OVA/alum 
sensitization, followed by three challenges on day 8, 9 and 10, with analysis on 
day 12 (43). However, if a model that involves two sensitizations (12 to 14 days 
apart) was investigated, most of the responses in ST2-deficient animals were 
similar to those in BALB/c mice (43, 65-66). These data suggest that, at least in 
animal models of asthma, the contribution of IL-33/ST2 pathway is 
indispensable in the acute phase of the antigen-driven responses, whereas in 
the chronic phase it can be compensated for by different inflammatory 
pathways. 
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Several groups assumed a different approach at investigating the role of the 
ST2/IL-33 pathway in asthma models and employed various techniques to 
transiently disrupt IL-33 signal, such as the use of anti-ST2 antibody (clone 
E310) (67-68), anti-IL-33 antibody (69), or soluble ST2-Fc fusion protein (64). 
Regardless of which particular technique was used to transiently block IL-33 
signal the differences include reduced eosinophil count and IL-5 levels detected 
in BAL fluid (64, 67, 69), reduced IL-4 in BAL fluid (64, 68-69), lower levels of 
IL-13 detected in BAL fluid, as well as systemically reduced OVA-specific IgE 
levels (67, 69), reduced airway hyper-responsiveness, mucus secretion and 
ST2+ cell infiltration in lungs (68), and reduced pulmonary inflammation (69). 
Thus, these studies confirmed the results obtained from ST2 deficient mice. 
While IL-33 acts on many different cell types in experimental asthma, the 
contribution of ST2/IL-33-activated T cells is among the most extensively 
studied aspects of the disease. By means of adoptive transfer of Th2 cells it 
was demonstrated that the response to OVA in recipient animals that had 
received either anti-ST2 antibody or ST2-IgG fusion protein is diminished, as 
reflected by reduced eosinophil numbers, reduced IL-4 and IL-5, as well as 
IL-6, IL-13 levels in BAL fluid (67, 70), while levels of IL-10 and IFN-γ remained 
unchanged (67). Moreover, it has been demonstrated recently that the 
resolution of allergic inflammation and airway hyperresponsiveness (AHR) 
depends on the neutralization of ST2/IL-33 pathway in T cells. This suggests 
that Il-33 is necessary not only for the development of allergic response but 
also for its maintenance (68). 
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In addition, a group from our own laboratory found that in the presence of 
antigen stimulation (OVA) or anti-CD3 antibody, IL-33 can potently drive a 
subpopulation of CD4+ cells that produce mainly IL-5 and IL-13 but not IL-4, 
which makes it distinct from the classical Th2 cells (43). Unlike Th2 cells, this 
IL-33-differentiated, IL-5-producing sub-population is entirely independent of 
IL-4 as it has been demonstrated to develop in IL-4-/- mice and, most 
importantly, could exacerbate OVA-induced airway inflammation both in IL-4-/- 
and WT background animals on a similar scale. The key role of IL-33 in the 
activation of those cells is consistent with the fact that IL-33 signaling does not 
induce GATA-3 or STAT6 factors, that classical Th2 cell population depend on. 
Furthermore, it was shown that dendritic cells (DCs) respond directly to IL-33 in 
a ST2-dependent manner and are capable of supporting the development of a 
IL-5+IL-4- Th2 cell subset (71). Therefore, these studies provide a possible 
mechanism explaining the existence and activation of IL-5-producing T cells in 
IL-4-deficient mice in different disease models (72-76). In the light of an 
increasing interest in different pathological phenotypes of asthma, further 
clinical studies into the contribution of the classical Th2 versus IL-33-triggered 
IL-4-independent T cells to airway inflammation may provide important insights 
into the etiology of different phenotypes of asthma, and may offer a novel 
therapeutic approach (77). 
Along with Th2 activation, IL-33 strongly affects the innate arm of type 2 
immunity, causing splenomegaly, blood eosinophilia and pulmonary 
inflammation as demonstrated by the administration of IL-33 to naïve mice (4, 
43) and later confirmed in transgenic mice that overexpress IL-33 (78). 
Furthermore, IL-33 was reported to induce goblet cell hyperplasia and massive 
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mucus overproduction in the lungs and stomach (4). Several groups 
demonstrated that those changes could be attributed to the activation of mast 
cells (29), basophils (79), and epithelial cells (80). For instance, IL-33 is capable 
of mast cell degranulation, independent of T or B cells although it does require 
sustained exposure to IgE. Furthermore, IL-33 triggers the release of 
leukotriens (LTB4) and prostaglandin D2 (PGD2) and stimulates mast cells to 
secrete an array of cytokines, such as IL-1β, IL-3, IL-6, TNF-α and chemokines, 
such as MIP-2α (CXCL2), MCP-1 (CCL2) and MIP-1α (CCL3), in an NF-κB 
dependent manner. It also induces the release of IL-5, IL-13, and chemokines, 
Eotaxin-2 (CCL24), RANTES (CCL5) and TARC (CCL17), through the MAP kinase 
pathway and independent of NF-κB (29). Interestingly, IL-33 was found 
substantially elevated in atopic patients during systemic (anaphylactic) shock or 
in atopic dermatitis patients but not in subjects without ongoing inflammation. 
Consistently, in the murine models of systemic anaphylaxis the response to 
allergen was effectively attenuated by the use of a soluble decoy IL-33 receptor 
(sST2), anti-IL-33 antibody or mast cell depletion. Thus, IL-33 appears to be an 
important molecule in the pathogenesis of IgE- and mast cell-associated 
diseases and may represent a useful target for drugs aimed at preventing an 
anaphylactic shock (29). 
As for the basophils, it was shown recently that IL-33 can act on freshly sorted 
murine bone marrow basophils without any priming with IL-3 or FcεR 
cross-linking and it stimulates the release of substantial amounts of histamine, 
IL-4 and IL-6 from these cells, thereby mimicking the response to GM-CSF, at 
least in the murine system. Also, IL-33 expands basophil population in the 
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murine bone marrow in vivo, through an indirect mechanism dependent on 
common β chain that is shared between receptors for IL-3, IL-5 and GM-CSF 
(79). 
Human basophils, on the other hand, do not express IL-33 receptor 
constitutively but its expression is IL-3-inducible. Yet, they readily respond to 
IL-33, without prior priming, and the outcome is very similar to that exerted by 
IL-3, namely, the secretion of IL-4, IL-8 and IL-13. However, IL-33 does not 
prime human basophils for C5a-triggered LTC4 release (81). 
IL-33 was also shown to promote histamine release triggered by antigen-bound 
(cross-linked) IgE. Moreover, IL-33 can trigger migratory responses of human 
basophils by inducing CD11b that is thought to regulate their adhesiveness to 
endothelial cells thereby facilitating basophil transmigration from blood to 
tissues. Furthermore, it was reported that IL-33 enhanced basophil migration 
along the gradient of Eotaxin (CCL11), although no apparent change in CCR3 
expression was observed (82). 
Taken together, there is growing evidence that IL-33 is one of the important 
factors that are capable of modulating allergic inflammation by skewing the 
balance of adoptive responses towards type 2 and/or by acting directly on 
several innate cells that contribute to the pathogenesis of lung inflammatory 
disease. 
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1.1.7.2.  Helminthic infections 
The process of developing an effective immunity against helminth parasites 
depends upon the host’s ability to mount an effective T helper 
type 2-associated cytokine response as well as the activation of innate immune 
cells. Recently, IL-33 joined other type 2 cytokines such as IL-4, IL-9, IL-13, 
IL-25 on a list of essential factors known to facilitate worm expulsion. IL-33 
seems to play a particular role in fighting gastrointestinal helminths, such as 
Trichuris muris where it shifts the balance toward Th2 cells producing IL-4, 
IL-9, and IL-13. Moreover, exogenous IL-33 induced the expression of thymic 
stromal lymphopoietin (TSLP) from epithelial cells of the infected caecum which 
itself is important for the generation of Th2-driven parasite immunity. 
Interestingly, IL-33 can also act independent of T cells, as demonstrated in 
SCID mice by increasing intestinal epithelium cell proliferation and crypt length, 
particularly in the initiation phase of the infection (83).  
More recently, by employing novel IL-13-eGFP reporter mice Neill et al. 
identified a distinct subset of Th2-inducible innate effector cells, named 
nuocytes that may represent the predominant early source of IL-13 during 
helminth infection with Nippostrongylus brasiliensis. Nuocyte leukocytes expand 
rapidly in response to IL-33 and IL-25 and fail to develop in the combined 
absence of these two cytokines causing a severe defect in worm expulsion (84). 
Taken together, the above data suggest that IL-33 is essential for the 
development of immunity against helminth parasites by activation Th2 cells, 
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epithelial cells and nuocytes. A summary of IL-33 biology is shown in 
Figure 1.2. 
1.2. Eosinophil 
Eosinophils have long been considered merely a type of terminally differentiated 
effector cells specialized in host defence against parasite helminths. However, 
there is now growing evidence to support the notion of a much more complex 
role that eosinophils play in the immune system as they seem to be involved in 
both adaptive and innate arms of immunity. 
1.2.1. Eosinophil development 
Eosinophil differentiation process occurs in the bone marrow and is induced and 
sustained by several cytokines and growth factors. It is now well established 
that three closely related cytokines, namely IL-3, IL-5 and GM-CSF, play a 
major role in controlling eosinophilopoiesis. Several reports clearly 
demonstrated that IL-5 is the most specific and most effective factor that 
controls both eosinophil differentiation and recruitment in vivo (85-88). 
Produced mainly by activated T cells and mast cells, IL-5 exerts its effect in the 
bone marrow by stimulating the expansion of a narrow pool of 
IL-5Rα-expressing eosinophil progenitor (hEoPs) cells that had differentiated 
under the control of more pluripotent cytokines and growth factors, including 
IL-3, CM-CSF, stem cell factor (SCF) and FMS-like tyrosine kinase 3 ligand 
(FLT3-L) (89). IL-5Rα expression is regarded a prerequisite and early 
lineage-specific event during the course of eosinophilopoiesis (90-91), (Figure 
1.3.). 
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In the human system, EoPs differentiate from IL-5Rα- common myeloid 
progenitor (CMP) cells (92), that were defined by Mori et al. as 
IL-5Rα+CD34+CD38+IL-3Rα+CD45RA--expressing cells (91), (Figure 1.3.). 
In the mouse system, eosinophils originate from the eosinophil 
lineage-committed progenitors (mEoPs) which arise downstream of 
granulocyte/macrophage progenitors (GMPs) and are CD117+ (c-kit-positive) 
cells (Figure 1.3.). Thus, unlike in human hematopoiesis, murine eosinophils, 
neutrophils and monocytes all originate from GMP cells. The precursor cells 
(mEoPs) that give rise to murine eosinophils were defined as 
(Lineage-Sca-1-) IL-5Rα+CD34+CD117low, and are characterized by the 
activation of GATA-1 transcription factor (90). 
Despite the fact that eosinophil development pathways differ considerably 
between the human and mouse in regard to the precise distribution of 
immediate precursor populations, a range of transcription factors involved in 
eosinophilopoiesis appears to be conserved across the two species. In 
particular, a highly coordinated expression of several transcription factors, 
including PU.1 (93-96), CCAAT enhancer-binding protein α (C/EBP-α and 
C/EBP-β) (95, 97-98) and the lineage-instructing GATA-1 (95, 99-101) allows 
for the commitment to eosinophil lineage and terminal eosinophil 
differentiation. 
Another GATA-1 closely related transcription regulator, called friend of GATA-1 
(FOG-1) acts as GATA-1 antagonist and has to be downregulated to allow for 
the eosinophil lineage commitment (102). Decidedly, GATA-1 transcription 
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factor plays a central role for eosinophil generation (103). This suggestion was 
confirmed by a study on the targeted deletion of high-affinity GATA-binding site 
(so-called double GATA site) which is commonly spread across many 
eosinophil-related genes, including major basic protein (MBP), CCR3, IL-5Rα 
chain and in the GATA-1 gene promoter itself. The deletion of a double GATA 
site abrogates eosinophil lineage development in vivo in so-called ∆dblGATA 
mice (95, 101, 103). Deficiency for C/EBP-α exerts a more broad effect 
preventing the differentiation of any granulocyte sub-populations, including 
eosinophils (104). The disruption of PU.1 gene also can significantly impair 
terminal differentiation of eosinophil. In eosinophil lineage committed cells, 
PU.1 appears to combine its effect with GATA-1 to produce the characteristics 
typical of eosinophil leukocyte, whereas in most other cells the two transcription 
factors mutually antagonize one another, where PU.1 represents the myeloid 
and GATA-1 the erythroid differentiation choice (95). Interestingly, the level of 
GATA-1 transcription required for eosinophil lineage commitment has to be just 
right, and can be characterized as low to moderate, with no FOG-1 expressed. 
There are data suggesting that moderate GATA-1 expression is both 
indispensable and sufficient for driving eosinophil development (105). Beyond 
the commitment of common myeloid progenitors to eosinophil lineage a 
different member of C/EBP family, more specifically, certain isoforms of C/EBP-ε 
transcription factor are required for terminal differentiation and functional 
maturation of human eosinophils while other forms counteract terminal 
differentiation (106). Moreover, mice deficient for this transcription factor lack 
both mature eosinophils and neutrophils (104, 107). Finally, loss of C/EBP-ε 
function caused by a known human SNP leads to the failure of secondary 
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granule proteins expression (both in the eosinophil and neutrophil lineages) in 
patients with so called specific granule deficiency (SGD) (108). 
In 2008, another transcription factor, Icsbp (interferon consensus sequence 
binding protein; also known as IFN response factor-8) was reported to be 
essential for eosinophil development as Icsbp deficient mice have a lower 
number of eosinophil progenitor cells, compared to wild type as well as exhibit 
lower eosinophil counts in a steady-state and fail to produce eosinophilia in 
response to nematode Nippostrongylus brasiliensis, despite high amounts of 
IL-5 expressed upon infection (109). Authors suggest that Icsbp controls 
GATA-1 expression. 
This precisely balanced interplay between GATA-1 FOG-1, PU.1, C/EBPα, Icsbp 
and C/EBP-ε transcription factors, both in terms of their relative expression 
levels and timing, is essential for effective eosinophil generation. The end-result 
is the development of a unique eosinophil lineage-affiliated pattern of gene 
expression where genes such as eosinophil peroxidase (EPO), and major basic 
protein (MBP) are exclusive to eosinophil lineage while several other 
granulocyte-associated genes are permanently shut down in eosinophils, such 
as basophil-specific histidine decarboxylase (HDC), neutrophil-specific 
myeloperoxidase (MPO) and mast cell-specific proteinases. This unique gene 
pattern was used to molecularly engineer a mouse strain specifically devoid of 
eosinophil, so-called PHIL mice, by linking the expression of bacteria-derived 
toxin with the expression of EPO, thus preventing eosinophils from undergoing 
maturation process (110). 
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1.2.2. Eosinophil recruitment and trafficking 
Terminal stages of eosinophil maturation seem to be inherently linked to 
eosinophil exit from the bone marrow into the circulation. This is largely 
dependent on the combinatorial action of cytokines, such as IL-5 and other Th2 
cytokines, IL-4 and IL-13, chemokines, in particular of eotaxin family and 
RANTES (111), and several adhesion molecules such as α4, β-1, β-2 and β-7 
integrins (112) and surface markers, such as CCR3 (113-115). Again, IL-5 
appears to be the central cytokine in eosinophil recruitment and trafficking as 
IL-5 deficient mice exhibit markedly reduced numbers of both circulating 
eosinophils and bone marrow resident eosinophil precursors (116). This was 
further confirmed in the human system in trials of anti-IL-5 therapy 
(mepolizumab) when decreased eosinophil counts were reported in the 
bronchial mucosa of atopic asthmatics (117-118). Along with IL-5 also the 
eotaxins are well recognized as the most lineage-specific factors that control 
eosinophil mobilization, trafficking and survival in the tissue, e.g. lung 
infiltration following antigen exposure (119-120). Their chemotactic effects are 
mediated by the G protein-coupled membrane bound receptor, CCR3 (121-
123). It is noteworthy that several CCR3 ligands, particularly eotaxin-1 (CCL11) 
and eotaxin-2 (CCL24) cooperate with IL-5 in orchestrating eosinophil 
trafficking and tissue accumulation by expanding the CCR3+ pool and/or 
priming eosinophils to respond to eotaxins (111). Interestingly, while CCR3 
signaling usually results in the activation and prolonged survival of eosinophil, 
more recent studies reported that CCR3 can also mediate strong negative signal 
able to arrest key eosinophil responses, particularly when Mig (CXCL9) 
chemokine acts as a ligand, through a Rac2 dependent pathway (124). In 
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humans, eosinophil trafficking is also regulated by eotaxin-3 (CCL26), which is 
only distantly related to the other two mentioned previously and it does not 
have a functional counterpart in mouse (125).  
Eotaxins are able to synergize with IL-5 to induce IL-13 production in the lung. 
In turn, IL-13 can synergize with IL-4 to potently induce eotaxins in the lung 
tissue through the STAT6-dependent mechanism which partially explains the 
causative relationship between Th2 responses and associated lung eosinophilia 
(111). This finding was further confirmed in IL-4 reporter mice infected with the 
migrating intestinal helminth, Nippostrongylus brasiliensis where eosinophil and 
Th2 cell recruitment into the lung was shown to be dependent on STAT6 
expression by bone marrow-derived tissue resident cells (that were 
characterized as non-T, non-B cells) (126). 
Importantly, in the course of antigen-induced airway inflammation, Th2 
cell-derived IL-13 facilitates eosinophil trafficking from peripheral blood into the 
lungs by controlling the expression of eotaxin and eotaxin-2. Each of those 
chemokines is responsible for eosinophil trafficking into a different lung 
compartment. While eotaxin expression appears to be induced in lung 
pneumocytes, the expression of eotaxin-2 occurs in alveolar macrophages 
(luminal inflammatory cells). Consistently, mice deficient for eotaxin-2 show 
markedly reduced BAL eosinophilia upon IL-13 administration (127). 
An interesting example of a surface marker involved in eosinophil trafficking is a 
sialic acid-binding immunoglobulin-like lectin, Siglec-F (and its human functional 
paralog Siglec-8). This sialoadhesin is markedly upregulated on blood and bone 
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marrow eosinophils in response to the induction of allergic lung inflammation 
despite its well established role as part of a negative eosinophil regulation both 
in vitro and in vivo (128-129). 
1.2.3. The effector functions of eosinophils 
Current knowledge about this highly specialized yet multifunctional leukocyte is 
still expanding. At homeostatic baseline, eosinophils are commonly found in the 
bone marrow where they constitute a small but stable sub-population that 
consists of both mature eosinophil cells and also eosinophil lineage precursors 
at various stages of development. As mentioned in previous section, rapid 
expansion of this population upon diverse stimuli, the most specific of which is 
IL-5, serves as a major, and probably the only, source of terminally 
differentiated eosinophil leukocytes that are subsequently recruited to the sites 
of inflammation mobilized by a range of chemokines, such as eotaxin, together 
with several adhesion molecules. Outside the bone marrow, eosinophils 
normally constitute 1-5% of blood nucleated cells and resident populations of 
tissue eosinophils are commonly found in the gastrointestinal tract (GI), 
particularly in the transitional area between the small intestine and the colon 
(cecum). These are also present in thymus, spleen, lymph nodes and 
endometrial lining of the uterus (endometrial stroma) (130-131) and are 
required for postnatal mammary gland development (132). Although it is a 
long-known phenomenon that eosinophils can be recruited in response to tissue 
damage and tissue repair, the details about the nature of their involvement in 
those processes are incomplete and poorly understood (133-136). In addition, 
eosinophil major basic protein (MBP) have been implicated as a pro-angiogenic 
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factor, based on evidence from in vitro and in vivo studies which may be of 
particular relevance to tissue repair and remodelling that contributes to asthma 
pathology (137). 
Eosinophils are widely recognized as the major effector cells in type 2 
inflammatory diseases, including helminthic infection, asthma, and allergy (130, 
138). The important role of eosinophils in the immunopathogenesis of asthma 
was shown in studies using eosinophil-deficient mice that develop markedly 
attenuated responses in experimental airway inflammation models (110, 139).  
Two distinct mouse strains devoid of eosinophils have been generated using 
different molecular approaches. In one case, mice harbor targeted mutations in 
the gene encoding a transcription factor GATA-1 (∆dblGATA mice) (139-140). 
In so-called PHIL mice, on the other hand, eosinophil ablation was achieved 
through the lineage-specific expression of the diphtheria toxin A chain, under 
control of the eosinophil peroxidase promoter (110). The latter strain (on a 
C57BL/6 background), is fully protected from airway hyperresponsiveness 
(AHR) and exhibits diminished airway mucous metaplasia as well as Th2 
cytokine levels in OVA-induced airway inflammation. Similar phenotype 
characterized by reduced AHR as well as diminished IL-4, IL-5 and IL-13 
production was reported in ∆dblGATA mice if bred on C57BL/6 (140). In 
contrast, ∆dblGATA mice on the BALB/c background develop AHR and mucus 
production comparable to WT mice in OVA-induced airway inflammation model 
(139). However, they showed reduced lung remodeling (which was not tested 
in PHIL mice). The above studies suggest that on the C57BL/6 but not BALB/c 
background, eosinophils are essential to the development of allergic airway 
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inflammation. These differences in phenotype between the two ∆dblGATA 
mouse strains may also provide an insight into why there is no direct correlation 
between lung eosinophilia and the severity of asthma in a subset of asthma 
patients treated with IL-5 blocking monoclonal antibody (141). 
In asthma, eosinophils mediate the inflammatory process through the release of 
cytotoxic granules and lipid mediators that induce tissue damage and affect 
nerves, which, in turn, causes bronchoconstriction (129-130, 138, 142-143). In 
addition, eosinophils show numerous immune regulatory functions, including 
the production of a range of cytokines and chemokines that leads to the 
exacerbation of inflammation, mucus secretion, and lung remodelling (129-130, 
138, 143). Recently, it was demonstrated that bone marrow eosinophils are 
essential for the survival of plasma cells through the release of the proliferation-
inducing ligand APRIL and IL-6; eosinophil-deficient mice exhibit much lower 
numbers of plasma cells both in the resting BM and after immunization (144). 
Thus, eosinophils support humoral immune response thereby helping to ensure 
long-term protection against pathogens. 
Eosinophils are also one of the primary sources of IL-4 during the initiation 
phase of type 2 immune responses (126), and they can recruit T cells by 
releasing TARC (CCL17) locally into the lungs during asthma development 
(145). There is also growing evidence that eosinophils can serve as antigen 
presenting cells (146). A summary of the multiple effector functions of 
eosinophils in the airways is shown in Figure 1.4. 
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1.3. Macrophage 
1.3.1. Macrophage subpopulations 
Macrophages are specialized hematopoietic cells distributed throughout 
different tissues of a body where they play central role in homeostasis, tissue 
remodelling and host defence. One of the key functional characteristics of 
macrophages is that, depending on micro-environmental factors, they can be 
specifically polarized so they are able to deal with a particular stimulus in a 
most adequate manner (147). In addition, the heterogeneity of circulating 
monocytes may pre-define their polarization fate once they arrive at tissue 
(148-149). 
Polarized macrophages have been broadly classified as either M1 or M2 
macrophages. (see Figure 1.5.). Classically activated M1 macrophages were 
described as being responsive to type 1 inflammatory cytokines and microbial 
products, and by producing high levels of IL-12, whereas M2 macrophages 
have been generally characterized by their low expression of IL-12. M2 
macrophages can be further divided into three groups, based on the activation 
factors they are responsive to: M2a (alternatively activated macrophages, AAM) 
are induced by IL-4 or IL-13; M2b can be induced by immune complexes and 
agonists of TLRs or IL-1 receptors; M2c (immunosupressive) are induced by 
IL-10 or TGF-β or glucocorticoids (150-151). Furthermore, macrophage subsets 
differ in their receptor expression, cytokine and chemokine expression and in 
their effector functions (152). M1 macrophages are well defined as potent 
effector cells involved in responses against microorganisms and tumor cells as 
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well as in pathologic type 1 inflammation. Their inflammatory repertoire is 
characterized by the secretion of IL-12, TNF-α, IL-1β, IL-23, IL-6, IP-10, 
RANTES and the high expression of iNOS. M1 macrophages express many TLRs, 
including TLR2, and opsonic receptors such as CD16. In contrast, M2 
macrophages ameliorate type 1 inflammatory responses and adaptive 
immunity, and regulate type 2 immune responses, angiogenesis as well as 
tissue remodeling. Various subsets of M2 macrophages exhibit these general 
properties. Promotion of type 2 response in helminthic infection, allergy and 
asthma are typical of AAM, whereas suppression of both type 1 and 2 
inflammation is a predominant feature of M2c cells. The M2 macrophage profile 
and the AAM in particular can be characterized by abundant expression of non-
opsonic receptors such as the mannose receptor (MR; CD206) and CD163. 
Moreover, Arginase-I is upregulated in AAM and M2c macrophages, which 
results in generation of polyamines and proline by these cells, thereby 
contributing to wound healing and pathological fibrosis (150-153). 
A growing interest in the role and function of AAM in parasitic infection and 
asthma led to the identification of more specific markers for AAM.  The most 
relevant signature markers besides Arginase-I, MR and IL-4Rα are chitinase-like 
lectin Ym1, resistin-like secreted protein FIZZ1 and acidic mammalian chitinase 
(AMCase) (154). Furthermore, a distinct chemokine profile, including TARC 
(CCL17), MDC (CCL22) and Eotaxin-2 (CCL24), has been associated with AAM 
activation (152). 
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1.3.2. The role of alveolar macrophages in the regulation of 
immune response 
The function of the lungs is to allow the uptake of oxygen and the excretion of 
carbon dioxide. With its large surface area, the lungs are exposed to many 
pathogens as well as harmless antigens. Since oedema and inflammation can 
lead to the thickening of alveolar walls and compromise gas exchange, immune 
defence of this barrier has to be tightly controlled (155). A cellular component 
of the immune response in the lungs consists mainly of alveolar macrophages 
which adhere closely to alveolar epithelial cells. It has been shown that to avoid 
damage to alveoli, alveolar macrophages are generally kept in a quiescent state 
which resembles M2c phenotype (immunosuppressive) (156). By producing 
cytokines such TGF-β1 they actively suppress the induction of adaptive 
immunity to harmless antigens through their effects on alveolar and interstitial 
DCs and T cells (156-158). However, in the presence of ‘danger signal’ which 
either comes from a pathogen or damaged tissues, alveolar macrophages are 
believed to be responsible for the initiation of the inflammatory response (159-
162). 
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1.4. Aims of the project 
Numerous clinical studies and animal models revealed much of the complexity 
of the asthma and allergic diseases including a prominent role of adaptive arm 
of immunity, in particular, Th2 cells but also cells associated with innate 
immunity such as eosinophils, mast cells, and macrophages. All those cell 
populations were thought to be driven chiefly by cytokines and other mediators 
derived from allergen-activated Th2 cells, in particular by IL-5, IL-4 and IL-13. 
Among those cytokines, IL-5 is widely recognized as one of the key factors that 
drive asthma pathogenesis owing to its known activity as a selective 
eosinophilopoietin and chemoattractant, thus required for eosinophil infiltration 
of the airways that eventually leads to profound histological changes including 
airway hyperresponsiveness, excessive mucus production and airway tissue 
remodeling. Indeed, atopic patients often exhibit elevated levels of serum IL-5 
which was commonly associated with high eosinophil counts in the sputum and 
more frequent asthma exacerbation episodes. Furthermore, data obtained from 
mouse airway inflammation models suggested that disrupting the IL-5 signaling 
may constitute an effective therapeutic approach through controlling airway 
eosinophilia.  
However, clinical investigations revealed that the use of monoclonal anti-IL-5 
antibody in asthma patients is not necessarily the best way to control eosinophil 
counts and/or eosinophil activation status in the airways (163-165). This may 
have been partially due to the reported a decrease in the IL-5Rα expression in 
the airways (166) in conjunction with a possible compensative increase in blood 
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IL-5 (suggestive of ‘endogenous’ IL-5 auto regulatory pathway) (167), which 
could not be counteracted with anti-IL-5 administration. Thus, the strategy 
aimed at preventing pathological changes in the atopic airways by controlling 
eosinophil population trough disrupting the signaling of IL-5 has been deemed 
insufficient. 
Recent studies, including those carried out in our laboratory suggest that there 
are, in fact, other factors that may contribute to asthma pathology. For 
instance, a recently discovered interleukin-33 was found to be markedly 
elevated in lung epithelial cells of asthma patients compared to healthy donors 
(Figure 1.1.), which strongly suggested that it may play a role in asthma 
pathogenesis through interfering with a local microenvironment of the airways. 
Indeed, we further demonstrated that IL-33 can profoundly alter the activation 
status of alveolar macrophages which, in turn, contributes to airway 
inflammation (26). Furthermore, IL-33 has been shown to induce IL-5 and 
IL-13 in CD4+ cells (43) and serves as a T cell chemoatractant (168) thereby 
contributing to antigen-driven airway inflammation. 
The main aims of this thesis therefore, were to further characterize the role of 
IL-33 in airway inflammation, by (I) investigating the mechanism in which this 
cytokine drives the differentiation of alveolar macrophages toward alternatively 
activated (M2) macrophages and (II) how this affects airway cellular 
composition. Furthermore, since eosinophilia seems to be a prerequisite for 
several pathological changes in asthmatic lungs, including airway 
hyperresponsiveness and airway tissue fibrosis, I sought to investigate (III) 
how IL-33 contributes to eosinophil biology and (IV) how, in turn, 
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IL-33-induced eosinophil mediators affect airways homeostasis. To do this I 
employed a cell specific depletion method or an adoptive cell transfer method 
followed by the intranasal administration of IL-33 which mimics much of the 
allergic airway inflammation characteristics (4, 26, 43, 48).  
Chapter 3 of this thesis provides information about the role of alveolar 
macrophages in the IL-33-induced airway inflammation. Chapter 4 investigates 
the effects of IL-33 on the population of eosinophil progenitor cells in the bone 
marrow and provides an insight onto the role of IL-33 in eosinophil trafficking 
through the regulation of the expression of CCR3, a key chemokine receptor 
involved in this process. Chapter 5 describes my studies of how IL-33 induces 
eosinophil activation and how some of the key eosinophil effector functions are 
regulated by IL-33 through ST2 receptor expressed on those cells. Finally, 
Chapter 6 provides an insight into the role of IL-33-activated eosinophils 
in vivo, as evaluated in IL-33-dependent airway inflammation model. 
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Fig. 1.1. Asthma patients express more IL-33 in the lung epithelial cells 
compared to healthy subjects. A-C, Frozen sections of lung biopsies of 
asthmatic patients and healthy donors were stained with anti-IL-33 antibody. 
Quantitative evalauation (A) and representative staining (B and C) are shown. 
Positive signal is violet. Data are means ± SEM (n = 10); *, p < 0.05, asthmatic 
versus controls. After Mariola Kurowska-Stolarska et al. (26), PMID: 19841166. 
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Fig. 1.2. IL-33 biology: target cells and cell-specific effects 
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Fig. 1.3. Eosinophil development in the human and mouse system 
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Fig. 1.4. Eosinophil effector molecules and their biologic effects in the lungs 
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Fig. 1.5. Macrophage subpopulations and their effector functions 
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Chapter 2: 
Materials and methods 
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2.1. Animals 
Wild type (WT) BALB/c mice were purchased from Harlan Olac, (Bicester, UK). 
ST2 gene knockout (ST2-/-) mice on the BALB/c background that harbor a 
deletion within the ST2 gene spanning across exon 4 and 5 (169) were 
obtained previously from Professor Andrew MacKenzie (Laboratory of Molecular 
Biology, MRC, University of Cambridge) and housed in the Biological Services 
facilities of the University of Glasgow in accordance with the United Kingdom 
Home Office regulations under the Animals (Scientific Procedures) Act 1986. All 
procedures were carried out under Project Licence Number 60/3791, 
Procedure 3 and Procedure 5. 
Bone marrow from C57BL/6, IL-13-/- and IL-5/IL-9/IL-13-/- triple knockout mice 
on the C57BL/6 background (170-171) were kindly provided by 
Professor Andrew McKenzie. 
2.2. Recombinant IL-33 
Human and murine recombinant IL-33 used in all in vivo experiments were 
produced in our laboratory according to published protocols (26, 168). 
Recombinant IL-33 used for all in vitro experiments was purchased from 
PeproTech (Rocky Hill, NY). Purity and biological activity of the two reagents 
was similar, as evaluated by its ability to induce IL-5 production from wild type 
but not ST2-/- cells. 
In brief, the IL-33 generation protocol was as follows: mouse cDNA for IL-33 
was cloned from IL-1-stimulated fibroblasts, and the cDNA template was 
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transformed into Escherichia coli. IL-33 protein was induced by IPTG and 
purified by Ni-NTA affinity chromatography. Traces of contaminating bacterial 
endotoxin were removed by passing the isolate through a polymyxin B column. 
Typically, the purity of IL-33 was more than 95% and endotoxin levels were 
less than 0.01 EU/µg of protein as evaluated by the Limulus Amebocyte Lysate 
QCL-1000 pyrogen test (Bio-Whittaker, Bio-Whittaker). 
2.3. Reagents and buffers 
All reagents, including buffered saline solutions were sourced from 
Sigma-Aldrich (Poole, UK). Culture media were purchased from Invitrogen Ltd 
(Paisley, UK), unless specified otherwise.  
Full list of chemicals used throughout the project includes: Phosphate buffered 
saline (PBS; 8g NaCl, 1.16g Na2HPO4, 0.2g KCl, 0.2g KH2PO4 in 1 litre distilled 
water, pH 7.4); Complete medium (500 ml RPMI 1640, 50 ml inactivated FBS, 
5ml pen / strep, 5 ml L-glutamine); BD ELISA Coating buffer (0.1M NaHCO3 pH 
8.4); ELISA Wash buffer (0.05% Tween-20 in PBS pH 7.4); BD ELISA assay 
buffer (10% FCS in PBS); R&D ELISA assay buffer (1% BSA in PBS); Biousource 
ELISA assay buffer (0.5% BSA and 0.1% Tween in PBS); Substrate solution 
(1.8mM o-phenylenediamine (OPD), 0.4mM H2O2 in 0.1M PBS containing 0.1% 
Triton-X-100, pH 8.0); 4M sulfuric acid; Formalin-acetone buffer (0.75 mM 
Na2HPO4, 7.5 mM KH2PO4, pH 7.4, 45% v/v acetone, 10% w/v formaldehyde); 
DAB/H2O2 phosphate buffer (0.60 mM Na2HPO4, 7 mM KH2PO4, pH 7.5, 2 mM 
3,’3’-diaminobenzidine tetrahydrochloride); 0.01% H2O2 (prepared afresh from 
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30% v/v solution); 8 mM potassium cyanide (KCN); Avertin stock (1:1 w/v 
solution of 2,2,2-tribromoethanol in tert-amyl alcohol). 
2.4. Cell isolation and enrichment 
2.4.1. Purification of mouse haematopoietic precursor cells 
Mice were sacrificed using carbon dioxide inhalation and the femur and tibia 
were aseptically removed from both hind limbs and stored in complete medium 
at 4OC until the bone marrow was extracted. Under sterile conditions, bones 
were cut open from both ends and the shaft was flushed with pre-chilled sterile 
BPS using a needle and a syringe. Single-cell suspension was achieved by 
passing the cells through a sterile 70µm nylon mesh (Costar). Then, cells were 
washed in 50ml of RPMI 1640 medium, centrifuged at 300g for 10 min at 4OC 
and resuspended in complete medium prior to counting in a haemocytometer. 
For CD117-positive (Lin-CD117+) cell enrichment, murine BM cells were 
separated using MACS Miltenyi magnetic cell sorter. The protocol recommended 
by the manufacturer was closely followed (MACS Miltenyi Biotec). In brief, BM 
cells were passed through 30µm nylon mesh (# 130-0141-407, Miltenyi Biotec) 
to remove the clumps and obtain a single-cell suspension. Next, lineage–
committed cells were depleted using the Lineage Cell Depletion Kit, mouse 
(#130-090-858, Miltenyi Biotec). Lineage-positive cells that express antigens 
from a panel of so-called ‘lineage’ antigens (CD5, CD45R (B220), CD11b, 
Anti-Gr-1 (Ly-6G/C) and Ter-119 antibodies) retained on a MACS column, while 
lineage-negative cells were allowed to pass through the column (separation by 
negative selection). In the following step, lineage-negative cells were enriched 
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for CD117 antigen using CD117 MicroBeads, mouse (#130-091-224, 
Miltenyi Biotec) by positive selection. 
2.4.2. Purification of mouse eosinophils 
Mouse eosinophils were obtained from bone marrow or peritoneal wash of WT 
and ST2-/- mice that have been injected with IL-5 (2µg/mouse, i.p.) or with 
IL-33 (2µg/mouse, i.p.) over 7 days. Eosinophil leukocytes were separated 
using a flow cytometry based cell sorter (Becton Dickinson, FACSAria One). In 
brief, cells were gated for Siglec-F+ or Siglec-F+ and CCR3high or Siglec-F+, 
CCR3high and Gr-1intermediate and sorted into medium containing GM-CSF (1ng/ml) 
or IL-5 (2ng/ml), to maintain cell viability. The purity ranged from 96 to 98%. 
Details are provided in the sections below. 
2.4.3. Purification of human eosinophils 
Human eosinophils were acquired from peripheral blood of healthy volunteers 
by density gradient centrifugation (Histopaque, density 1.077 g/ml). In brief, 
20ml of cell suspension were carefully laid over 20ml of Histopaque-1077 
solution and in a 50 mL conical tube and centrifuged at 600×g for 30 minutes 
at 20OC in a swinging bucket rotor without brake. This was followed by the lysis 
of erythrocytes from the bottom fraction in ammonium chloride erythrocyte lysis 
solution (0.8% NH4Cl, 10mM KHCO3 and 0.1mM EDTA) in a fully-filled 50ml 
conical tube (10minutes, on ice) and centrifugation at 300×g for 8 minutes. 
Cells were then washed by adding 50 ml of MACS Running Buffer (Miltenyi 
Biotec), spun down again, re-suspended in appropriate volume of Running 
Buffer and counted. Next, eosinophils were magnetically separated from other 
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granulocytes using Eosinophil Isolation Kit, human (# 130-092-010, Miltenyi 
Biotec) based on a panel of antibodies consisting of CD2, CD14, CD16, CD19, 
CD56, CD123, and CD235a (glycophorin A) designed for the negative selection 
of human eosinophils. Instructions provided by the manufacturer were closely 
followed to achieve efficient separation. Actual purity of eosinophil population 
was verified by differential cell staining or staining for eosinophil-specific 
cyanide resistant peroxidase (EPO) activity of cytospin preparations. The purity 
ranged from 96 to 98%. 
2.5. Cell cultures 
2.5.1. Eosinophil development from whole bone marrow and 
CD117+ precursors 
Whole bone marrow (2x106/well/1ml) or purified CD117+ haemopoietic cells 
(0.5x106/well/1ml, purity ≥95%) from BALB/c, ST2-/-, IL-13-/- and 
IL-5/IL-9/IL-13-/- were cultured in RPMI 1640 (supplemented with 10% FCS, 
2mM L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 0.05M 
2-mercaptoethanol) and IL-5 (10ng/ml) or IL-33 (2, 10, 50ng/ml) (all cytokines 
from Peprotech) ± anti-IL-5 neutralizing antibody or isotype control (10µg/ml, 
eBioscience). After 4-5 or 7-8 days of culture, cells were stained with 
PE-conjugated anti-Siglec-F (early eosinophil differentiation marker; BD 
Bioscience), APC-conjugated anti-CCR3 (an eosinophil marker; R&D Systems), 
FITC-conjugated anti-ST2L (MD Bioscience), PerCP-conjugated anti-Gr-1 
(a granulocyte marker; BD Bioscience), PE-conjugated anti-FcεR1 (a basophil 
marker, BD Bioscience), or with the appropriate isotype control followed by 
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FACS analysis (Table 2.1.). To analyze the effect of IL-33 on CCR3 expression, 
cells from WT and ST2-/- bone marrow culture driven with IL-5 (10ng/ml) were 
resuspended, in PBS/2% FCS (50x106/ml) and 20µl of PE-conjugated rat 
anti-mouse Siglec-F antibody per 50x106 cells were added. Cells were incubated 
for 30min on ice followed by two washing steps (10ml of PBS/2% FCS; 10min, 
300g). After the last washing step cells were resuspended in PBS (50x106/ml) 
and then equal amount of Cell Dissociation Solution (Sigma) was added to 
prevent forming cell clumps. The cells were then sorted by FACS, based on high 
Siglec-F expression into complete medium supplemented with IL-5 (2ng/ml) to 
prevent cell death. Purity of sorted cells was evaluated and was ≥98%. Cells 
were then stimulated with IL-33 (10ng/ml) in media containing small amount of 
IL-5 (2ng/ml). After 24h, the cells were stained with APC-conjugated anti-CCR3 
antibody (4µl/100µl) for 30 minutes followed by two washing steps (10ml of 
PBS/2% FCS; 10 minutes, 300g). Cytospins were prepared from some cultures 
and stained in the presence of potassium cyanide for EPO (specific for 
eosinophils) or were differentially stained with eosin/hematoxylin. 
2.5.2. Eosinophil cytokine responses and surface markers  
WT and ST2-/- mice were injected with IL-5 (2µg) i.p. every second day for 
7 days. Twenty four hours after last injection cells were harvested from bone 
marrow. Cells were then resuspended in PBS/2% FCS (50x106/ml) and 20µl of 
PE-conjugated rat anti-mouse Siglec-F antibody (0.2mg/ml; BD Bioscience) and 
40µl APC-conjugated rat anti-mouse CCR3 (R&D Systems) per 1ml (50x106 
cells) were added. Cells were incubated for 30 minutes on ice followed by two 
washing steps (10ml of PBS/2% FCS; 10 minutes at 300g). After last washing 
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step cells were resuspended in PBS (50x106/ml). Next, equal volume of Cell 
Dissociation Solution (Sigma) was added to prevent forming cell clumps. The 
cells were then sorted by FACS, based on high Siglec-F and CCR3 expression 
into complete medium containing 1ng/ml of GM-CSF or 2ng/ml of IL-5 to 
prevent cell death. Purified populations of eosinophils (purity ≥97%, 
0.5x106/well/ml) were cultured in IL-5-containing control medium (2ng/ml), 
supplemented with GM-CSF (1, 10ng/ml) or IL-4 (10ng/ml) or IL-33 (10, 
50ng/ml) or a combination of these cytokines. After 24 or 48h, cells were 
stained with FITC-conjugated anti-ST2L and APC-conjugated anti-CCR3 
followed by FACS analysis (see Table 2.1. for details). To assay cytokine and 
chemokine production, purified eosinophils were incubated in medium with 
GM-CSF (1ng/ml, survival and ST2L inducing factor; control) ± IL-33 (10, 
50ng/ml). After 48h culture supernatants were collected. Cell viability was 
evaluated by counting in trypan blue and was ≥94%. Levels of cytokine and 
chemokine production were evaluated after 72 hours of culture by 20-plex 
Luminex (Biosource) or ELISA using paired antibodies against IL-13 , TGF-β1, 
IL-4 and chemokines MIP-1α, Eotaxin-1, Eotaxin-2, TARC (see Table 2.2. for 
details).  
2.5.3. Eosinophil degranulation 
Mature human and mouse eosinophils were cultured in the presence of GM-CSF 
(1ng/ml) ± IL-33 (50ng/ml) as before. After 24h, cells were washed with fresh 
RPMI medium and seeded into a plate coated with anti-human CD32 or anti-
mouse CD32/16 (0.3 or 1µg/ml) or mIgG1 or hIgG1 (1µg/ml). After 90 minutes 
culture supernatants were collected and EPO assay performed. The amount of 
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EPO in the degranulation assay was calculated as the percentage of 
total EPO released from eosinophils that underwent 3 freeze-thaw cycles. EPO 
colorimetric assay was performed on cell supernatants according to previously 
published protocol (172). In brief, aliquots of sample (50µl) were incubated 
with equal volume (50µl) of substrate solution containing 1.8mM 
o-phenylenediamine (OPD) and 0.4mM H2O2 in 0.1M phosphate buffer 
containing 0.1% Triton-X-100 (pH 8.0) for 30min at 37°C followed by 
acidification with 4M sulfuric acid. Results are shown as the percentage of total 
EPO. Cell viability was evaluated by differential cell counts using trypan blue. 
In some cultures, cells pre-incubated with GM-CSF±IL-33 were stained with 
PE-conjugated anti-CD32 or PE-conjugated anti-CD16 antibodies followed by 
FACS analysis (see details in Table 2.1.). 
 2.5.4. Macrophage differentiation in vitro 
Bone marrow cells from WT or ST2-/- were cultured in RPMI 1640 supplemented 
with 10% FCS, 2mM L-glutamine, 100units/ml penicillin, 100µg/ml 
streptomycin, 0.05 M 2-mercaptoethanol on Petri dishes 10x106 per 5ml per 
dish in the presence of M-CSF (10ng/ml). After 3 days, cells were fed with 5ml 
of fresh complete medium supplemented with M-CSF (10ng/ml). On day 6 of 
culture, cells were evaluated by flow cytometry (FACS) for macrophage marker 
and cell preparations containing ≥96% of F4/80+ macrophages were used for 
further experiments. 
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2.5.5. Co-culture of eosinophils and macrophages 
Specially designed culture plates with well inserts were used throughout the 
co-culture experiment series (Transwell system, 12-well plate, Costar). Upper 
compartment contained murine wild type eosinophils of 3x106/0.5 ml per well. 
A small pore diameter (0.4µm), permeable membrane was designed to prohibit 
cell migration between the compartments without restricting the diffusion of 
soluble mediators. Lower compartment contained 0.5x106/well/1.5ml of ST2-/- 
macrophages. Cells were incubated with IL-5 (10ng/ml) or IL-33 (10ng/ml) ± 
neutralizing anti-IL-13 antibodies (R&D Systems) or isotype controls (both 
10µg/ml) for 72h. The expression of TLR2 (eBioscience, clone 6C2) and 
mannose receptor (MR) (Serotec) on macrophages was then analyzed by FACS 
(Table 2.1.). 
2.6. Murine model of allergic asthma 
WT and ST2-/- mice were given i.p. injections with 100µg of OVA (Sigma) in 2% 
alum (Aluminium Hydroxide Gel Adjuvant, Brenntag) and then challenged i.n. 
on days 8, 9 and 10 with 10µg of OVA or PBS as described previously (173). 
Mice were sacrificed 48-120 h after the last challenge. Bronchoalveolar lavage 
(BAL) fluid was collected and analyzed. 
Mice were terminally anaesthetized by the i.p. injection of 500µl of Avertin 
(2,2,2-Tribromoethanol, Sigma-Aldrich, 20mg/ml working solution in PBS, filter 
sterilized through a 0.5 micron filter, Millipore) then killed by exsanguinations 
after anesthetized sufficiently (no toe pinch/righting reflex, typically after about 
5 minutes). Next, the trachea was exposed and a small incision made at the 
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proximal end to allow cannulation with a 23G needle sheathed with polythene 
tubing (VWR International). Then, a volume of 0.8ml of PBS was instilled into 
the lungs for about 15 seconds and the fluid was aspirated. Subsequently, a 
second aliquot of 0.8ml of fresh PBS was instilled as in the previous step. The 
two aspirated aliquots were then pooled in a 1.5ml centrifuge tube and stored 
on ice until the next step was carried out. Live cell counts were performed in a 
haemocytometer using trypan blue. Cells were spun onto glass slides using a 
Shandon Cytospin 3 (Shandon Scientific Limited, Cheshire, UK) at 450 rpm for 8 
minutes. Then, slides were air dried and cells were fixed by incubation in 
methanol at room temperature over 10 minutes. Slides were then stained by 
the Romanovsky method using Rapi-Diff II (BIOS Europe Limited, Lancashire, 
UK). Coverslips were affixed onto the air-dried slides using DPX (BDH 
Laboratory Supplies, Poole, UK). 
In addition, BAL cells were stained with PE-conjugated anti-Siglec-F and 
APC-conjugated anti-CCR3 and FITC-conjugated anti-ST2L antibodies 
(Table 2.1.) or matching isotype control. 
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2.7. IL-33-induced airway inflammation 
IL-33 (2µg/mouse) or PBS was administered intranasally for 3 consecutive days. 
To evaluate the contribution of IL-13 to IL-33-induced inflammation, mice were 
given neutralizing antibodies or appropriate isotype controls (20µg/mouse) 
together with IL-33. To evaluate the contribution of alveolar macrophages to 
IL-33-induced airway inflammation, clodronate or control liposomes 
(40µl/mouse) were administered i.n. 72 and 24 hours prior to three intranasal 
IL-33 inoculations over the next three consecutive days (one IL-33 inoculation 
daily; see Figure 2.1. below). Clodronate compound was a gift of 
Roche Diagnostics GmbH, Mannheim, Germany. All mice were sacrificed on 
day 6 and, bronchoalveolar lavage fluids were analyzed. Cells from BAL were 
counted using a hemocytometer as detailed in previous section. Cytospin 
preparations were made using a Cytospin 3 apparatus and stained with 
Diff-Quick (Triangle Biomedical Sciences) in a rapid Romanowsky staining 
method (see section 2.6. for details). Differential cell counts were carried out 
using standard morphological criteria. 
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Figure 2.1. Intranasal instillation of clodronate liposomes into alveolar 
compartment. The depleting effect typically lasts up to 7 days. Two weeks prior 
to the first clodronate injection and during the experiment mice were kept in 
filtered cages and given sterile food and water. The 3-dose-6-day protocol for 
intranasal IL-33 administration was designed and optimised on the basis of the 
previous dose response and time course experiments that had been carried out 
by other members of our laboratory, namely Nick Pitman, Peter Kewin and 
Grace Murphy (unpublished data). These data indicated that the midpoint of 
eosinophil response occurs three days after the last intranasal IL-33 
administration and it is moderate in magnitude, compared to a 7 day model, 
which was an advantage in terms of animal welfare and corresponded better to 
the features of clinical asthma. 
Cull 
Clodronate 
or PBS 
(40µl) i.n. 
Clodronate 
or PBS 
(40µl) i.n. 
IL-33 dosing: 
3x2µg/mouse, once 
daily 
     2          1           0            1                              3                           6 
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Figure 2.2. Intranasal instillation of clodronate liposomes (adapted from 
http://www.clodronateliposomes.org/, by Dr. Nico van Rooijen). The method 
allows for a specific depletion of alveolar macrophages without affecting 
macrophage populations in any other compartment. Key: cL = clodronate 
liposomes; TR = trachea 
TR 
alveolar space 
lung parenhyma 
cL 
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2.8. Adoptive transfer of eosinophils 
BALB/c mice (n=10) were injected with mIL-33 (2µg) intraperitoneally for 
7 days. Twenty four hours after last injection cells were harvested from 
peritoneal wash. Cells were then resuspended in PBS/2% FCS (50x106/ml) and 
20µl of PE-conjugated rat-anti-mouse Siglec-F antibody (0.2mg/ml; BD 
Bioscience) and 40µl of APC-conjugated rat anti-mouse CCR3 (R&D Systems) 
per 1ml (50x106 cells) were added. Cells were incubated for 30 minutes on ice 
followed by two washing steps (10ml of PBS/2% FCS; 10 minutes, 300g). After 
last washing steps cells were resuspended in PBS (50x106/ml) and them equal 
amount of Cell Dissociation Solution (Sigma) was added to prevent forming cell 
clumps. The cells were then sorted by FACSA, based on high Siglec-F and CCR3 
expression into complete medium containing 1ng/ml of GM-CSF to prevent cell 
death. Purity of sorted cells was evaluated and was ≥98%. The cells were then 
incubated 2 days with GM-CSF (1ng/ml), stained with CFSE (2µM) and 
administered intranasally to ST2-/- recipients (10x106/mouse). IL-33 
(2µg/mouse) or PBS were administered intranasally on day 1, 2, and 3. Control 
recipient mice received PBS instead of cells followed by IL-33 or PBS 
inoculations. All mice were sacrificed on day 4 and BAL fluids were analyzed as 
described previously (see section 2.6. for details). BAL cells were stained with 
FITC-conjugated anti-F4/80 antibodies and PE-conjugated anti-TLR2 and 
APC-conjugated anti-MR or APC-conjugated anti-CD4 or isotype controls 
(Table 2.1.). 
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2.9. Flow cytometry (FACS) 
Cells from each sample were washed with FACS Staining Buffer (2% FCS in 
PBS, 0.09M NaN3), resuspended in 100µl of FACS Staining buffer and incubated 
with FcBlocker (anti mouse CD32/16 2µl/tube, BD Pharmingen). After 
10 minutes specific fluorochrome-conjugated anitibodies or isotype controls 
were added for further 30 minute incubation, followed by two washing steps in 
staining buffer (1ml/tube). After washing, the cells were resuspended in 400µl 
of staining buffer and analyzed by flow cytometry (FACSCalibur). To enable 
dead cell exclusion, 2µl of 7-Amino-actinomycin-D (7-AAD, Via-probe, BD 
Biosciences) was added to each FACS tube immediately before acquiring and 
analysis on FACSCalibur flow cytometer (BD Biosciences). All data analysis was 
carried out using the FlowJo software (Tree Star Inc., Oregon, USA) or 
CellQuest (BD Biosciences). Details concerning antibodies used for FACS 
staining are summarized in Table 2.1. 
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Antigen Label Isotype Stock Volume/100
µl 
Company 
mST2L 
hST2L 
FITC rat IgG1 
mouse IgG1 
1mg/ml 2µl MD Bioscience 
mCCR3 APC rat IgG2a 25µg/ml 4µl R&D Systems 
mSiglec-
F 
PE rat IgG2a 0.2mg/ml 2µl BD Biosciences 
mGr-1 PerCP rat IgG2b 0.2mg/ml 2µl BD Biosciences 
hCD69 APC mouse IgG1 0.2mg/ml 5µl BD Biosciences 
hCD32 PE mouse IgG1 100 tests 2µl BD Biosciences 
hCD16 PE mouse IgG1 100 tests 2µl BD Biosciences 
mFcεR1 PE Rat IgG 0.2mg/ml 2µl BD Biosciences 
mF4/80 APC rat IgG2b 0.2mg/ml 2µl AbD Serotec 
mMR Alexa64
7 
rat IgG2a 50µg/ml 10µl AbD Serotec 
mCD11c FITC Hamster 
IgG1 
0.2mg/ml 2µl BD Biosciences 
mTLR2 FITC rat IgG2b 0.2mg/ml 2µl eBioscience 
 
Table 2.1. Monoclonal antibodies used for flow cytometry.  
                Key: m = mouse; h = human 
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2.10. Cytokine immunoassays 
Cytokine and chemokine contents in culture supernatants was assessed by 
means of enzyme linked immunosorbent assay (ELISA) kits, ELISA paired 
antibodies and multiplexed immunoassay. The latter will be described in a next 
paragraph while this section provides details about standard ELISA protocols. 
In regard to antibody pairs from BD Biosciences, all reagents and samples were 
applied at a volume of 50µl/well. Flat-bottomed ELISA plates (Immulon 4 HBX, 
Thermo Labsystems, Franklin, USA) were coated with capture antibody in BD 
ELISA coating buffer (0.1M NaHCO3 pH 8.4) and incubated overnight at 4OC. 
Plates were washed three times with ELISA wash buffer (0.05% Tween-20 in 
PBS pH 7.4) and incubated 1 hour at 37OC with 300µl/well of assay buffer (1% 
BSA in PBS). Following the blocking step, plates were washed three times and 
samples and standards were added. A 7 point doubling dilution standard curve 
in duplicates was used. Assay buffer served as blank (also in duplicates) and for 
the dilution of the standards. Samples and standards were incubated for 2 
hours at room temperature after which plates were washed five times and 
biotinylated detection antibody diluted in assay buffer was added to all wells 
and incubated for 2 hours at room temperature. Subsequently, plates were 
washed three times and Streptavidin-HRP conjugate (Extravidin, Sigma) was 
added in 1:1000 dilution. After 30 minutes of incubation at room temperature 
plates were washed three times and 100µl/well of TMB substrate was added 
(KPL, Gaithersburg, USA). Plates were developed in the dark for a maximum of 
30 minutes. Some assays were terminated earlier if blue colour had become 
clearly visible. Optical density was measured using an MRX II microplate reader 
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(Dynex Technologies, Worthing, UK) at 630nm wavelength. Sample values were 
calculated from the standard curves using Revelation software package (Dynex 
Technologies).  
Similar protocol was followed for R&D antibodies except for the different ELISA 
assay buffer that was used (see Table 2.2.). Also, the supplied Eotaxin-2 
detection antibody required dilution in the R&D ELISA assay buffer containing 
2% normal goat serum. The latter had to be heat-inactivated and cooled down 
to room temperature prior to antibody dilution. 
All antibody pairs used are detailed in Table 2.2.  
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Analyte 
Capture Ab 
(µg/ml) 
Detection Ab 
(µg/ml) 
Sensitivity 
(pg/ml) 
Company 
mIl-4 2 2 20-20x103 BD Biosciences 
mIL-5 4 4 10-10x103 BD Biosciences 
mIL-6 1 1 10-10x103 BD Biosciences 
mIFN-γ 1 1 40-40x103 BD Biosciences 
mIL-13 kit kit 5-5x103 R&D Systems 
mMIP-1α kit kit 5-5x103 R&D Systems 
mEotaxin-1 0.8 0.4 5-0.5x103 R&D Systems 
mEotaxin-2 2 0.08 4-4x103 R&D Systems 
mTARC 2 0.2 5-1x103 R&D Systems 
mTGF-β1 4 0.2 15-1.5x103 R&D Systems 
 
Table 2.2. Monoclonal antibody pairs used for ELISA. 
              Key: m = murine 
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2.11. Multiplexed immunoassay (Luminex) 
This type of an immunoassay utilizes specific antibodies for the cytokines and 
chemokines of choice that have been coated on the designated beads that had 
been coded with a characteristic combination of fluorescent dyes. Such 
modification to classical ELISA allows for the simultaneous identification of 
multiple ligands in a single reaction volume.  
All culture supernatants were collected and stored at -20OC until they were 
assayed using LMC006 (Cytokine Mouse 20-Plex). Full list of cytokines present 
on the Luminex plate included IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IFN-γ, IL-1β, 
IL-6, IL-8, TNF-α, VEGF, IL-17, FGF, IL-1α and chemokines: KC, MCP-1, MIG, 
MIP-1α and IP-10. The assay was used according to the manufacturer’s 
instructions. All reagents and solutions required were purchased from the 
original kits. A 96-well Luminex filter plate was pre-washed with Wash solution 
using vacuum apparatus. Next, 50µl of fluorescent bead mixture was added into 
each well and washed twice with Wash solution. Subsequently, the following 
reagents were added per well: 50µl of Incubation Buffer, 100µl of standard or 
50µl of Assay Diluent plus 50µl of sample. Mixtures of fluorescent beads with 
samples or standards were then incubated at room temperature for 2 hours 
with agitation in the dark. Subsequently, the wells were washed twice and 
100µl per well of biotinylated detection antibody was added and incubated for 1 
hour as previously. Then, the plate wells were washed twice and 100µl per well 
of Streptavidin-HRP was added and incubated for another 30 minutes as before. 
Next, the wells were washed three times before resuspending the beads in 
100µl per well of Wash solution. The fluorescence bound to the beads was 
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analysed using a Luminex 100 analyse (Luminex Corporation, Texas, USA). 
Data was then analysed by means of Luminex software (Luminex Corporation). 
 
2.12.  Staining for cyanide-resistant eosinophil peroxidase 
Cytospin preparations of 1-5x104 cells were prepared using a Cytospin 3 
apparatus (Shandon Scientific Limited, Cheshire, UK). Slides were fixed for 
0.5min in ice-cold (4OC) formalin-acetone buffer (see section 2.3. for details). 
Next, slides were washed with room temperature tap water and air dried. 
Subsequently, cells were stained for eosinophil-specific, cyanide-resistant 
peroxidase activity using a previously described method (174-175); the validity 
of this method was also verified in human cells (176-177). Briefly, cytospin 
preparations were incubated in DAB/H2O2-containing phosphate buffer 
supplemented with low concentration of KCN for 10 minutes (KCN was used 
instead of NaCN as the source of cyanide ion). Subsequently, slides were 
washed by shortly immersing in fresh tap water, then briefly under running tap 
water, and air dried. Finally, cells were counterstained with hematoxylin and 
cover slips were affixed onto the air-dried slides using DPX (BDH Laboratory 
Supplies, Poole, UK). 
Precautions were taken to avoid contact with the poison, and a cyanide 
antidote was also kept available. At the conclusion of these experiments, all 
cyanide-containing solutions were disposed of in accordance with relevant 
safety regulations by technical staff. 
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2.13. Extraction of RNA 
Freshly isolated human peripheral blood neutrophils and eosinophils were 
washed twice with PBS, gently centrifuged, and PBS residues were completely 
removed by aspiration. Cells were lysed in RLT solution (Qiagen), and stored at 
-20OC until they were processed. The RNA isolation was carried out using the 
RNeasy Micro Kit (Qiagen) according to the protocol provided by the 
manufacturer. Unwanted genomic DNA was removed by carrying out an 
optional step with the RNAse-free DNase set (Qiagen) as recommend in the 
original manufacturer’s protocol. The RNA contents and its quality was 
measured using a NanoDrop 2000c instrument (Thermo Fisher Scientific). 
Samples were then stored at -80OC until processed. 
 
2.14. Reverse transcription polymerase chain reaction 
(RT-PCR) 
RNA samples were thawed and kept on ice until used as template in a reverse 
transcription using Superscript II Reverse Transcriptase set (Invitrogen) 
according to the manufacturer’s protocol. The reaction mixture comprised of 
300ng of RNA template, 1µg Oligo(dT) (500µg/ml), 1µl of dNTP mix (25mM 
each) and nuclease-free water (Qiagen). A total volume was 12µl per reaction, 
placed in a nuclease-free microcentrifuge tube (ABgene, Surrey, UK). The 
mixture was incubated in 65OC for 5 minutes then rapidly cooled to 4OC. Next, 
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4µl volume of 5X First-Strand Buffer, 2µl of 0.1M DTT and 1µl of RNase 
inhibitor (40 units/ml) were added and incubated at 42OC for two minutes. 
Subsequently, 1µl (200 units) of Superscript II RT was then added and 
incubated at 42OC for 50 minutes. The reaction was then terminated by 
incubation at 70OC for 15 minutes. Tubes containing PCR mixture with no 
Superscript II served as negative controls. cDNA was then stored at -80OC.  
 
2.15. ST2L- and sST2-specific cDNA amplification (PCR) 
AmpliTaq Gold 360 DNA Polymerase (Invitrogen) was used to amplify cDNA 
transcripts of interest. The original manufacturer’s protocol was followed. In 
short, reaction mixture (total of 25µl) consisted of 12.4µl nuclease-free water 
(Qiagen), 2.5µl AmpliTaq Gold 360 Buffer (10x), 2µl Magnesium Chloride 
(25mM), 2µl dNTP mix (10-mM, 2.5mM each; final concentration 200µm each), 
2µl forward primer (final concentration 1.0µM), 2µl reverse primer (final 
concentration 1.0µM), 0.1µl (1U), AmpliTag Gold 360 DNA Polymerase, and 2µl 
cDNA template. Each polymerase chain reaction was performed using standard 
cycle conditions suggested by the polymerase manufacturer (holding, 
10min/95OC for AmpliTaq Gold activation; cycling: 35x denature, 30sec/95OC 
anneal, 30sec/58OC, extend, 30sec/72OC; final extension, 7min/72OC; final 
hold/4OC). Amplifications were carried out using a Veriti 96-well Thermal Cycler 
(Applied Biosystems). Samples were normalized by reference to a housekeeping 
gene, β-actin, as a reporter gene. Primer pairs for human ST2L, sST2 and 
β-actin were validated and kindly provided by Mark Moore. 
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The amplified templates were then analyzed on a 2% agarose (Gibco) gel 
containing 0.8µg/ml ethidium bromide (Sigma) in 0.5 times TBE buffer. Gels 
were run on at 80V, powered by a constant power supply (Pharmacia). Gel was 
then visualised under ultra-violet (UV). 
2.16.  Statistical analysis 
Analysis of variance (ANOVA) followed by Tukey’s test or Student’s t-test was 
applied to the data. All data are expressed as mean ± SEM. p < 0.05 was 
considered statistically significant. 
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Chapter 3: 
The role of alveolar macrophages in IL-33-induced airway 
inflammation 
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3.1. Alveolar macrophages are required for IL-33-induced 
airway inflammation 
It has been previously reported that IL-33 is abundantly expressed in the lungs 
of asthma patients. Consistently, IL-33 overexpression or administration of 
exogenous IL-33 into the lungs leads to the development of symptoms that 
resemble key asthma features, such as lung eosinophilia, type 2 cytokine and 
chemokine production as well as the activation of epithelial cells (48, 178). 
However, it is still unclear which cell type is responsible for an initiation of this 
response. Using deficient mice or depletion antibodies Kondo et al excluded the 
contribution of T and B cells, NK cells, basophils and mast cells.  
Alveolar macrophages are predominant immune effector cell type resident in 
the alveolar spaces of the airways and it is believed that they are responsible 
for the initiation of inflammatory responses. We previously showed that IL-33 
can target macrophages and is a potent amplifier of bone marrow-derived and 
alveolar macrophage differentiation toward alternatively activated macrophage 
(AAM, M2) phenotype (26). Those cells are characterized by high expression of 
pro-fibrotic arginase-I and production of chemokines such as TARC (CCL17) and 
eotaxin-2 (CCL24) (26). Thus, I hypothesized that alveolar macrophages are 
the cell type that acts as the first line of response upon IL-33 release and, in 
turn, modulates subsequent immunological events. Naïve mice were 
administered with IL-33 (2µg i.n.) or PBS for 3 consecutive days and the mice 
were culled on day 6. Mice receiving IL-33 showed lung inflammation 
manifested by an increase in total BAL cell count, including eosinophil, 
macrophage and neutrophil cell counts (Figure 3.1.). In order to investigate 
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the contribution of alveolar macrophages to IL-33-induced airway inflammation, 
clodronate or control liposomes (40 µl/mouse) were administered intranasally 
72 and 24 h before three consecutive days of intranasal IL-33 inoculations as 
described by Thepen et al. (157). This route of liposome administration affects 
alveolar but not lung parenchyma macrophage (157) (Figure 2.2.). The 
intranasal administration of clodronate liposomes was able to deplete around 
80% of alveolar macrophages compared to the control group. Interestingly, 
IL-33 induced significantly less severe eosinophilia in alveolar 
macrophage-depleted mice compared to control mice (Fig. 3.2.) indicating that 
IL-33-driven AAM activation of alveolar macrophages is likely responsible for 
IL-33-induced airway eosinophilia. 
3.2. IL-33-induced airway inflammation and alternatively 
activated macrophage polarization are IL-13 dependent 
In our previous studies in vitro we were able to demonstrate that IL-13/IL-4Rα 
signaling is essential for IL-33-driven AAM activation by inducing the expression 
of ST2L (26). To confirm the contribution of IL-13 to IL-33-induced airway 
inflammation and alveolar macrophage differentiation in vivo, mice were given 
IL-13 neutralizing antibodies or appropriate isotype control (20 µg/mouse) for 5 
consecutive days. IL-33 was administered over the first three days. All mice 
were sacrificed on day 6. Neutralization of IL-13 significantly decreased total cell 
and eosinophil counts in the BAL by 45 and 55% respectively (Fig. 3.3.). 
Importantly, anti-IL-13 neutralizing antibodies markedly decreased the 
percentage of mannose receptor-positive (MR+) alveolar macrophages 
compared to the control group (54 ± 8% and 82 ± 2% of all macrophage, 
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respectively; p < 0.05). The percentage of TLR2-positive macrophages 
remained unchanged (Fig. 3.4.). These data demonstrate that IL-13 is 
required, at least partially, for IL-33-induced airway inflammation and 
differentiation of alveolar macrophages toward AAM. 
Summary of Chapter 3 
Together, these data indicate that IL-33/ST2 signaling plays a significant role in 
the polarization of alveolar macrophages toward AAM by acting via IL-13 
dependent mechanism. Most importantly, alveolar macrophages are likely the 
first line of response to IL-33 signal and as such are major factor that 
contributes to the initiation and maintenance of IL-33-induced airway 
inflammation. 
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Fig. 3.1. IL-33 induces airway inflammation. BALB/c mice were treated i.n. 
with IL-33 (2 µg/mouse) or PBS for 3 consecutive days (all groups n = 5). Mice 
were sacrificed on day 6. BAL differential cell counts are shown. Data are 
means ± SEM. *, p < 0.05 PBS versus IL-33-treated mice. 
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Fig. 3.2. A-B  Macrophage depletion results in diminished eosinophilia and 
lower total cell counts in BAL. Clodronate (n = 5) or control (n = 5) liposomes 
(both 40µl/mouse) were administered i.n. 72 and 24h before i.n. IL-33 
inoculation (3 consecutive days, 2µg/mouse/day). All mice were sacrificed on 
day 6 and BAL cells were analyzed. BAL differential cell counts are shown. 
A, Data are means ± SEM. *, p < 0.05, clodronate versus control liposomes. 
B, Representative data from FACS analysis of BAL cells is shown. 
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Fig. 3.3. The contribution of IL-13 to IL-33-induced airway inflammation. 
BALB/c mice were treated i.n. with IL-33 (2µg/mouse) or PBS for 3 consecutive 
days. Some mice also received anti-IL -13-neutralizing Abs (20µg/mouse) for 
5 consecutive days. The control group received isotype-matched rat IgG (all 
groups n = 5). Mice were sacrificed on day 6. BAL differential cell counts are 
shown. Data are means ± SEM. #, p < 0.05 IL-13 neutralizing Abs versus 
IgG-treated mice. 
ce
lls
 x
 1
0
5
/m
l 
ce
lls
 x
 1
0
5
/m
l 
 93 
 
 
 
 
 
 
 
 
Fig. 3.4. IL-33-induced differentiation of alveolar macrophages toward AAM is 
diminished by IL-13 neutralization. BALB/c mice were treated i.n. with IL-33 
(2µg/mouse) or PBS for 3 consecutive days. Some mice also received 
anti-IL-13-neutralizing Abs (20µg/mouse) for 5 consecutive days. The control 
group received isotype-matched rat IgG (all groups n = 5). Mice were sacrificed 
on day 6. Representative staining for MR and TLR2 of alveolar macrophages 
from anti-IL-13 Abs and IgG-treated mice is shown. 
 94 
 
 
 
 
 
 
 
Chapter 4: 
The role of IL-33 in eosinophil development 
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4.1. IL-33 promotes eosinophil development in bone marrow 
IL-33 can induce eosinophilia in mice (4, 48, 80). I showed in Chapter 3 that 
IL-33-activated alveolar macrophages are responsible for attracting eosinophils 
from the periphery into lungs. However, it is still not clear whether IL-33 can 
directly affect eosinophil differentiation and activation. In this chapter I 
addressed the first part of this question by using several different methods and 
various eosinophil markers (89). Initially, I incubated whole bone marrow cells 
from WT or ST2-/- mice with IL-33 or IL-5 for 5 or 8 days. IL-5 and IL-33 
induced eosinophil differentiation from bone marrow precursors of WT mice as 
determined by the presence of eosinophil peroxidase (EPO, eosinophil 
granule-associated marker) (Fig. 4.1.). By contrast, IL-5 but not IL-33 induced 
eosinophil differentiation in ST2-/- mice. There were no EPO+ cells detected in 
the culture with medium alone in WT or ST2-/- cultures. These data indicate that 
IL-33 can induce eosinophil development from bone marrow cells in a 
ST2-dependent manner. 
 
4.2. IL-33 directly drives eosinophils from haemopoietic 
precursor cells (Lin-/CD117+) 
To determine whether IL-33 can act directly on hematopoietic progenitor cells, 
CD117+ (c-kit+) cells were purified from bone marrow of WT or ST2-/- mice after 
depletion of committed or mature lineage-positive cells and cultured as above. 
Freshly isolated BALB/c Lin-CD117+ progenitors expressed ST2L (Fig. 4.2.). 
The expression of IL-5Rα on these cells was below the detection level of flow 
 96 
cytometry (Fig. 4.3.). However, the expression of IL-5Rα was markedly 
increased in the cultures stimulated with IL-33 for 4 days (Fig. 4.4.). Eosinophil 
differentiation was analyzed by FACS using surface eosinophil-specific marker, 
Siglec-F. IL-5 could induce comparable numbers of Siglec-F+ cells that stained 
positively with eosin both in WT and ST2-/- CD117+ cell cultures (10 ± 2.5% 
and 9.2 ± 2.5% respectively), whereas IL-33 could induce 
Siglec-F+-eosin-positive eosinophils only in WT but not in ST2-/- CD117+ cell 
cultures (10.5 ± 0.5% and 1.2 ± 1% respectively) after 5 days of culture 
(Fig. 4.5., FACS; Fig. 4.7., quantitative diagram). The morphology of Siglec-F+ 
cells from IL-5- and IL-33-driven cultures matched typical eosinophil cell 
characteristics with pink-orange eosin-stained granules in the cytoplasm as 
shown in Fig. 4.6. Similar data were obtained for 8-day cultures; there were no 
live cells, including Siglec-F+, detected in 8-day cultures with medium alone 
(data not included). In addition, IL-33-driven Siglec-F+ eosinophils expressed 
ST2L (Fig. 4.8.). 
These results therefore indicate that IL-33 is able to act directly on 
hematopoietic progenitor cells and stimulate their differentiation to mature 
eosinophils. 
4.3. IL-33 driven eosinophil development is partially 
mediated by IL-5 
Given that IL-33 stimulates the production of cytokines associated with type 2 
immunity and eosinophil development (4, 43, 130), I examined the contribution 
of IL-5, IL-9 and IL-13 to the IL-33-induced development of eosinophils from 
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bone marrow precursors. Bone marrow cells from WT, IL-13-/- and 
IL-5/IL-9/IL-13-/- triple knockout mice were cultured with IL-33 (5 or 20ng/ml) 
or medium alone over 5 or 10 days and mature eosinophil population 
characterized by the expression of CCR3 was evaluated by FACS 
(CCR3+GR-1intermediate) and eosin-positive staining. IL-33 could induce 
comparable numbers of CCR3+Gr-1+ eosinophils from the precursors of IL-13-/- 
and WT mice (9.5 ± 2% and 9 ± 1.9% respectively), but not from the 
precursor cells of triple knockout mice (2.5 ± 1.5%) (Fig. 4.9.1-2.). These 
results suggest that IL-5 and/or IL-9 but not IL-13 are required for the 
IL-33-induced eosinophil differentiation from precursor cells. Since IL-5 is 
known as a major eosinophil differentiation factor (179), I cultured CD117+ 
hematopoietic progenitor cells with IL-33 in the presence of an IL-5-neutralizing 
antibody. The treatment with anti-IL-5 monoclonal antibody markedly reduced 
the IL-33-induced differentiation of eosinophils (SiglecF+CCR3+) from CD117+ 
cells (Fig. 4.10.). Consistent with this finding, WT CD117+ cells stimulated with 
IL-33 produced substantial amounts of IL-5 compared to un-stimulated cultures 
or IL-33-treated ST2-/- CD117+ cells (Fig. 4.11.). Furthermore, an increase in 
FcεRI-positive cells, likely basophils, were detected in cultures stimulated with 
IL-33 as reported previously by Schneider et al. (79), (Fig. 4.12.).  
Together, these data suggest that IL-33-driven eosinophils development from 
progenitor cells is ST2 and IL-5 but not IL-13 dependent. 
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4.4. IL-33/ST2 signaling is required for optimal expression 
of CCR3 on eosinophils 
CCR3 is a major chemokine receptor responsible for the mobilization of mature 
eosinophils from the bone marrow and their trafficking to sites of inflammation 
(130). To investigate whether IL-33 is involved in the regulation of CCR3 
expression during eosinophil differentiation, FACS-sorted Siglec-F+ eosinophils 
from IL-5 driven bone marrow cultures (7 days) were checked for characteristic 
eosinophil morphology (Fig. 4.13.) and incubated with IL-5 (2ng/ml) ± IL-33 
for 24h and CCR3 expression determined by FACS. As expected, the majority of 
IL-5-driven Siglec-F+ eosinophils readily expressed CCR3 (Fig. 4.14., 
histogram), however, IL-33 was able to further increase surface density of 
CCR3 on these eosinophils (Fig. 4.15., diagram). Next, I investigated whether 
there was any difference in the basal expression of CCR3 between IL-5-driven 
eosinophils from WT and ST2-/- mice. Eosinophils from ST2-/- mice expressed 
significantly less CCR3 than WT eosinophils (Fig. 4.16. and Fig. 4.17.). Thus, 
these results clearly indicate that the endogenous IL-33/ST2 signaling pathway 
enhances the expression of CCR3 on eosinophils. 
Summary of Chapter 4 
Together, this part of my study suggests that IL-33 is able to act locally in the 
bone marrow compartment and directly stimulates eosinophil differentiation 
from hematopoietic progenitor cells in an IL-5-dependent manner. 
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Fig. 4.1. IL-33 induces eosinophil differentiation from bone marrow cells. Bone 
marrow (2×106/ml) from WT or ST2-/- mice were cultured with IL-5 (10ng/ml) 
or IL-33 (10ng/ml) for 5 days. The cell number and dose of cytokines used 
were optimized in preliminary experiments (data not shown). EPO staining of 
cultured bone marrow cells is shown (original magnification × 10; insets × 40). 
Data are representative of three independent experiments. 
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Fig. 4.2. Freshly isolated Lin-CD117+ haematopoietic cells from WT mice readily 
express ST2L. Data are representative of three independent experiments. 
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Fig. 4.3. Freshly isolated Lin-CD117+ haematopoietic cells from WT mice do not 
express IL-5Rα at the level detectable by FACS. Data are representative of 
three independent experiments.  
         IL-5Rα 
ce
ll 
co
u
n
t 
 102 
 
 
 
 
 
 
 
 
 
Fig. 4.4. The expression of IL-5 receptor in CD117+ cells can be upregulated 
by IL-33 stimulation. Representative FACS analysis of CD117+ cultures with 
IL-33 on day 4 is shown. Data are representative of three independent 
experiments. 
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Fig. 4.5. IL-33 induces eosinophil differentiation from haematopoietic 
progenitor cells (FACS). Lin-CD117+ haematopoietic cells (0.5×106/ml) from 
BALB/c or ST2-/- mice were cultured with IL-5 (10ng/ml) or IL-33 (10ng/ml) for 
5 days. Representative FACS analysis of CD117+ cultures is shown. Data are 
representative of three independent experiments. 
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Fig. 4.6. Sorting eosinophils from Lin-CD117+ cells cultured in with IL-33. A-D, 
gating used for sorting Siglec-F+ cells; A, Cells gated for big, granule-containing 
cells in P1; B, cells from P1 stained with IgG-PE before sorting (isotype control); 
C, cells from P1 stained with Siglec-F-PE before sorting where gate P2 was used 
to sort for eosinophils; D, Siglec-F+ cells in gate P2 after sorting (returned 
sample); E, Eosin-stained cytoplasm and donut shaped nuclei of Siglec-F-sorted 
eosinophils obtained from cultures of WT CD117+ cells with IL-5 or IL-33; a 
representative image of Siglec-F+ cells shown (original magnification × 40). 
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Fig. 4.7. IL-33 induces eosinophil differentiation from haematopoietic 
progenitor cells. Quantitative evaluation of the eosinophil marker Siglec-F on 
CD117+ cells. CD117+ haematopoietic cells (0.5×106/ml) from BALB/c or ST2-/- 
mice were cultured with IL-5 (10ng/ml) or IL-33 (10ng/ml) for 5 days. Data are 
means ± SEM of three independent experiments. *p < 0.05, IL-33- or 
IL-5-treated versus medium; #p < 0.05, WT versus ST2-/- sample. 
Siglec-F-expressing cells (eosinophils) 
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Fig. 4.8. Siglec-F+ eosinophils that differentiate from Lin-CD117+ cells express 
ST2L. Lin-CD117+ hematopoietic cells (0.5×106/ml) from BALB/c mice were 
cultured with IL-5 (10ng/ml) or IL-33 (10ng/ml) for 5 days. Representative 
FACS analysis of CD117+ cultures is shown. Data are representative of three 
independent experiments. 
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Fig. 4.9.1.  IL-33-induced eosinophil differentiation from bone marrow cells is 
markedly inhibited in IL-5/IL-9/IL-13-/- triple knockout mice (5 days). Bone 
marrow cells (2×106/ml) from WT (C57BL/6 background), IL-13-/- (C57BL/6), or 
IL-5/IL-9/IL-13-/- triple knockout mice (C57BL/6) were cultured with IL-33 (5 or 
20ng/ml) or medium alone for 5 days. Representative data on the expression of 
eosinophil markers CCR3high and GR-1intermediate of a single experiment are 
shown. Technical duplicates were used to generate FACS data for each IL-33 
dose used. Eosin-stained CCR3high and GR-1intermediate-sorted cells (gate G1). 
Original magnification ×20; inset ×100. 
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Fig. 4.9.2.  IL-33-induced eosinophil differentiation from bone marrow cells is 
markedly inhibited in IL-5/IL-9/IL-13-/- triple knockout mice (10 days). Bone 
marrow cells (2×106/ml) from WT (C57BL/6 background), IL-13-/- (C57BL/6), or 
IL-5/IL-9/IL-13-/- triple knockout mice (C57BL/6) were cultured with IL-33 (5 or 
20ng/ml) or medium alone for 10 days. Representative data on the expression 
of eosinophil markers CCR3high and GR-1intermediate of a single experiment are 
shown. Technical duplicates were used to generate FACS data for each IL-33 
dose used. 
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Fig. 4.10. IL-33–induced eosinophil differentiation from haematopoietic 
progenitor cells is IL-5 dependent. CD117+ hematopoietic cells (0.5×106/ml) 
from BALB/c were cultured with IL-33 (10ng/ml) with or without 
IL-5-neutralizing Ab (or isotype control, 10µg/ml) for 5 days. Representative 
FACS data of mature eosinophil; Siglec-F and CCR3 markers are shown. Data 
are representative of three independent experiments. 
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Fig. 4.11. IL-33 induces IL-5 production by CD117+ cells. CD117+ 
haematopoietic cells (0.5×106/ml) from WT or ST2-/- (BALB/c background) mice 
were cultured with IL-33 (10 or 50ng/ml) for 5 days. IL-5 levels in culture 
supernatants were determined by ELISA. Data are means ± SEM of three 
independent experiments, *p < 0.05, IL-33 versus medium; #p < 0.05, WT 
versus ST2-/-. 
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Fig. 4.12. The effect of IL-33 on the development of basophils. A population of 
FcεRI-positive cells expands in cultures of WT but not ST2-/- cells when 
stimulated with IL-33. CD117
+
 cells were purified from bone marrow of WT and 
ST2-/- mice after the depletion of committed and mature lineage-positive cells 
and culture in the presence of IL-5 (10ng/ml) or IL-33 (10ng/ml) for 4 days. 
Cell phenotype was analysed by FACS using FITC-anti-CD-11c, PE-anti-FcεRI 
antibodies and relevant isotype controls. Data from a single experiment are 
shown. Similar results supporting IL-33-driven basophil differentiation were 
reported by Schneider et al. (79). 
 112 
 
 
 
 
 
 
 
Fig. 4.13. The purity of FACS-sorted eosinophils was confirmed by the 
presence of eosin (pink cytoplasm) as shown in this microphotography. WT 
bone marrow cells were cultured for 7 days with IL-5 (10ng/ml) followed by 
FACS-sorting for Siglec-F+ cells. Original magnification ×20; inset ×100). 
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Fig. 4.14. IL-33 increases eosinophil CCR3 expression (i). FACS-sorted 
Siglec-F+ eosinophils from IL-5-driven (10ng/ml) WT bone marrow cultures 
(7 days with IL-5) were incubated with IL-5 (2ng/ml) with or without IL-33 
(10ng/ml) for 24h, followed by FACS analysis for CCR3 expression. Expression 
of CCR3 by FACS is shown. Data are representative of three independent 
experiments. Control = IL-5 alone (2ng/ml, red line); IL-33 variant = 
IL-5+IL-33 (2 and 10ng/ml respectively, blue line); Isotype = grey line. 
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Fig. 4.15. IL-33 increases eosinophil CCR3 expression (ii). FACS-sorted 
Siglec-F+ eosinophils from IL-5-driven (10ng/ml) BALB/c bone marrow cultures 
(7 days with IL-5) were incubated with IL-5 (2ng/ml) with or without IL-33 
(10ng/ml) for 24h, followed by FACS analysis of CCR3 expression. Data are 
means ± SEM (n = 3),*p < 0.05, IL-5 versus IL-5 + IL-33 (white and black, 
respectively). 
(IL-5) 
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Fig. 4.16. IL-33 increases eosinophil CCR3 expression (iii). FACS-sorted 
Siglec-F+ eosinophils from IL-5-driven (10ng/ml) BALB/c and ST2-/- bone 
marrow cultures were FACS stained and checked for CCR3 expression. Data are 
representative of three independent experiments. 
 116 
 
 
 
 
 
 
 
 
 
Fig. 4.17. ST2-/- eosinophils expressed reduced levels of CCR3. 
FACS-sorted Siglec-F+ eosinophils from IL-5-driven (10ng/ml) WT and ST2-/- 
bone marrow cultures were checked for CCR3 expression. The percentage of 
CCR3high cells is shown. Data are means ± SEM (n = 3), #p < 0.05, WT versus 
ST2-/- of three independent experiments. 
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Chapter 5: 
The role of IL-33 in modulation  
of effector functions of eosinophil 
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5.1. The regulation of ST2L expression on mature human 
and murine eosinophils 
Next, I looked at the regulation of ST2 expression on mature human and 
murine eosinophils. Human peripheral blood (PB) eosinophils were isolated by 
negative selection (Miltenyi Biotec). The purity of eosinophils was evaluated by 
EPO and/or hematoxilin/eosin staining and showed ≥ 96% of cells positive for 
EPO and or eosin stained granules (Figure 5.1.). In contrast to PB neutrophils, 
eosinophil leukocytes easily expressed mRNA for ST2L and sST2 (Figure 5.2.). 
Subsequently, I evaluated surface expression of ST2L on human PB eosinophils 
isolated from 6 volunteers. PB eosinophils expressed ST2L protein only 
marginally (less than 2% of cells) in majority of donors (4 out of 6). However, 
in remaining 2 donors, between 2 and 15% eosinophils expressed ST2L 
(Figure 5.3., Figure 5.4.). Not surprisingly, the expression of ST2L on human 
eosinophils could be potently increased by the ST2L ligand itself. A small 
increase was also observed in the medium alone, suggesting that ST2L 
expression may be regulated by certain component(s) of fetal calf serum (FCS). 
Interestingly, IL-5 markedly decreased the medium-induced ST2L expression 
but this effect could be still overcome by the stimulating action of IL-33 
(Figure 5.3., Figure 5.4.). Similarly, murine mature eosinophils differentiated 
from bone marrow precursors in the presence of IL-5 and sorted by FACS for 
CCR3high Siglec-F+ cells (> 98% pure, Figure 5.5.), did not express detectable 
amounts of ST2L (Figure 5.6.). To investigate whether cytokines that are 
abundantly released during type 2 immune response can affect ST2L expression 
on murine eosinophils, I used IL-5-driven mature eosinophils from WT and 
ST2-/- mice and incubated those cells in medium containing IL-5 (2ng/ml) 
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supplemented with IL-33 or GM-CSF or IL-4 (all 10ng/ml) or a combination of 
these cytokines for 48h. Expression of ST2L on eosinophils incubated in 
medium with IL-5 alone was either below the sensitivity of FACS (Figure 5.6.) 
or was very low (Figure 4.8.). However, IL-33 (Figure 5.6.) and GM-CSF 
(Figure 5.7.) but not IL-4 (Figure 5.8.) increased ST2L expression on WT 
eosinophils. An additive effect of GM-CSF and IL-33 on ST2L expression was 
also observed in WT (Figure 5.7.) but not ST2-/- mice (Figure 5.9.). Taken 
together, these results demonstrate that mature human and mouse resting 
eosinophils express low levels of ST2L which can be markedly increased by 
cytokines including IL-33 and GM-CSF. 
 
5.2. BAL eosinophils express ST2L during OVA-induced 
airway inflammation 
To determine whether eosinophils that accumulate in the lungs during the 
course of inflammation actually express IL-33R I evaluated ST2L expression on 
BAL eosinophils during the course of mouse OVA-induced airway inflammation 
(see Materials and Methods). BAL cells were isolated 48-120 h after the last 
antigen challenge and the expression of ST2L on CCR3+ eosinophils was 
evaluated by FACS. Based on the previous data (26, 43) I expected eosinophils 
(CCR3+cells) to start accumulating in BAL as early as 24 h with a maximum 
120 h after the last challenge. BAL eosinophils expressed ST2L which was at its 
peak 48 h after the last challenge (80% of eosinophils) (Figure 5.10.) and 
gradually declined afterwards, down to nominal 2.5% on day 5. ST2L was not 
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detected in control eosinophils from ST2-/- mice. Thus, the kinetics of ST2L 
expression on eosinophils suggests that cytokines derived from OVA-activated 
T cells are likely responsible for the increase of ST2L expression on eosinophils 
that accumulated in the lungs. 
Altogether, these data suggest that in the course of type 2 immune response 
eosinophils that are mobilized to the site of inflammation may acquire ST2L on 
the surface likely due to cytokines produced by antigen-specific Th2 cells. 
 
5.3. The role of IL-33 in eosinophil activation 
5.3.1. IL-33 induces production of IL-13, IL-6, TGF-1β and 
TARC 
Since IL-33 is abundantly expressed in the lungs of asthma patients and mice 
with OVA-induced allergic inflammation (26-28, 43) and eosinophils at sites of 
inflammation express high levels of ST2L, (Figure 5.10.) I thus investigated 
the contribution of IL-33 to mature eosinophil function in more detail. 
Eosinophils are a source of pleiotropic mediators, including cytokines, 
chemokines and tissue damaging granule proteins (130). To investigate 
whether IL-33 can modulate the production of these mediators, FACS-sorted 
CCR3+Siglec-F+ WT and ST2-/- eosinophils were incubated in medium containing 
suboptimal amounts of GM-CSF (1ng/ml) in the presence or absence of IL-33 
(10, 50ng/ml) over 48h. GM-CSF was used because of its ability to act as 
eosinophil survival factor; it can also upregulate the expression of ST2L. 
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Evaluation of cytokine contents in culture supernatants (ELISA and Luminex 
assay) revealed that IL-33 triggered the production of IL-13 (Figure 5.11.), 
IL-6 (Figure 5.12.) and strongly increased the production of TARC and TGF-β 
(Figure 5.13, Figure 5.14. respectively) from WT but not ST2-/- eosinophils in 
a dose-dependent manner. IL-33 had little to no effect on the production of 
eotaxin, eotaxin-2, IL-4, MCP-1, IP-10 and MIP-1α (data not shown). Other 
cytokines (IL-17, KC, MIG, FGF, IL-1α, IL-2, IL-5, IL-10, IL-12, IFN-γ, IL-1β, 
TNF-α, VEGF) remained below the detection level of Luminex assay used (data 
not shown). These data indicate that IL-33-activated eosinophils may be an 
important source of IL-13, TARC, IL-6 and TGF-β. 
 
5.3.2. IL-33 exacerbates IgG-induced eosinophil 
degranulation 
It is well documented that eosinophils are source of tissue damaging granule 
proteins (130, 138, 143, 180-181). In order to evaluate the contribution of 
IL-33 to the process of eosinophil degranulation, mature murine eosinophils 
were cultured in the presence of GM-CSF (1ng/ml) ± IL-33 (50ng/ml) as before. 
After 24 h, cells were washed with fresh RPMI medium and seeded into a plate 
coated with anti-CD32/16 (0.3 or 1µg/ml) or mIgG1 (1µg/ml). After 90 minutes 
culture supernatants were collected and EPO assay performed. The amount of 
EPO in the degranulation assay was calculated as % of total EPO released from 
eosinophils that underwent 3 freeze-thaw cycles. In addition, the viability of 
cells was evaluated by cell counts using trypan blue. Both plate-bound 
anti-CD32/16- and IgG-triggered EPO release that was markedly increased in 
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the IL-33 pre-treated cells. However, trypan blue-staining showed that, in both 
instances, an increase in the EPO release from IL-33 pre-treated cells coincided 
with a higher cell death rate (Figure 5.15., Figure 5.16). Thus, the 
engagement of FcγII receptor on mouse eosinophils in vitro can lead to an 
increase in eosinophil cell death. However, a close comparison of the proportion 
of the amount of EPO released with the proportion of viable cells that remained 
in IL-33 pre-treated cultures suggest that there is some contribution of the 
degranulation-derived EPO. Also, I performed similar experiments in human 
eosinophils purified from peripheral blood. Again, pre-treatment of cells with 
hIL-33 increased EPO release by human eosinophils in anti-CD32 Ab-induced 
culture compared to non-treated cells (Figure 5.17.). In contrast to the murine 
system, there was no difference between the two pre-treatment conditions in 
anti-CD32 Abs induced cell death. Thus it appears that in human eosinophils, 
the contribution of apoptosis-derived EPO release is modest compared to 
IL-33-potentiated degranulation. 
 
These data suggest that IL-33 is, indeed able to significantly increase the 
IgG-triggered degranulation. In order to investigate the mechanism behind this 
process, I looked at the expression of FcγRs on human esoinophils. FACS 
analysis showed that the pre-treatment of human eosinophils with IL-33 
increased the expression of FcγRII receptor (CD32) but not FcγRIII (CD16) 
(Figure 5.18.) likely rendering these cells more responsive to IgG binding and 
thus promoting degranulation. 
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5.3.3. IL-33-activated eosinophils polarize macrophages into 
AAM in an IL-13 dependent manner 
In the course of IL-33-triggered airway inflammation as well as in OVA-induced 
asthma model alveolar and lung macrophages differentiate toward alternatively 
activated macrophages (M2, AAM) (26). This sub-population of macrophages is 
largely responsible for the production of chemokines and fibrotic factors that in 
turn perpetuate lung inflammation and fibrosis. Given the abundance of 
eosinophils in the lungs during asthma models I asked whether IL-33 
stimulated eosinophils contribute to the activation of macrophages. To test this 
hypothesis I co-cultured ST2-/- BM derived macrophages with WT eosinophils 
in vitro in the presence or absence of IL-33 or IL-5. Eosinophils alone modestly 
elevated the percentage of MR+ macrophages which was markedly increased by 
the presence of IL-33 but not IL-5 (Figure 5.19, Figure 5.20.). Furthermore, 
because IL-13 is a well-defined M2-differentiation factor (150) and was found to 
be produced by eosinophils upon IL-33 stimulation (Figure 5.13.), I therefore 
investigated whether IL-13 produced by IL-33-activated eosinophils may be 
responsible for the enhanced M2 (AAM) polarization. The presence of anti-IL-13 
neutralizing antibodies partially but significantly reduced the number of 
MR+ macrophages polarized by IL-33-activated eosinophils (Figure 5.21. and 
Figure 5.22.; assessed by ANOVA followed by Tukey’s test), indicating that 
IL-33- but not IL-5-activated eosinophils polarized macrophage to the 
pro-inflammatory AAM phenotype, at least in part, via IL-13. 
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5.3.4. IL-33 induces expression of activation marker CD69 on 
human peripheral blood eosinophils 
Also, I have preliminarily looked at the role of IL-33 in human PB eosinophils 
activation. I decided to evaluate the expression of CD69 as it was reported in 
the literature to be an early activation marker of human eosinophils (182). Its 
expression is elevated in response to several cytokines including IL-13 (183), 
GM-CSF, IL-3, IL-5 in vitro and in vivo in BAL fluid of asthma patients (184). PB 
eosinophils were stimulated with hIL-5 (10ng/ml) or hIL-33 (10 and 50ng/ml) 
for 48h. Eosinophils cultured in medium alone expressed low levels of CD69 on 
the surface. IL-5 strongly increased the expression of CD69. Similarly, IL-33 
significantly increased the expression of CD69, primarily on ST2L positive 
eosinophils. These data therefore indicate that indeed IL-33 affects the 
activation of human eosinophils (Figure 5.23., Figure 5.24). 
 
Summary of Chapter 5 
Together, this part of my study demonstrates that IL-33 enhances multiple 
features of eosinophil functions including cytokine/chemokine production, 
interaction with other cell types as well as degranulation and therefore an 
IL-33-rich environment in asthma and allergy may contribute to the pathogenic 
activities of eosinophils. 
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Fig. 5.1. The evaluation of the purity of human eosinophils isolated from 
peripheral blood. Specific staining for eosinophil peroxidase (EPO) is shown in 
the upper panel; eosinophil EPO-containing granules stain in red-gold. Bottom 
panel shows a classical differential eosin/hematoxylin staining. Left panel, 
original magnification x 10; right panel, original magnification x20. 
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Fig. 5.2. The expression of ST2L and sST2 mRNA can be detected in freshly 
isolated eosinophils but not neutrophils. Specific band of 175 bp (line 5) 
represents PCR product of ST2L. Similarly, the band of 149 bp (line 12) 
represents PCR product of sST2. Lines 4, 11 contain DNA marker 
(1kb DNA ladder). Lines 1, 2, 8, 9 contain positive control (housekeeping gene, 
β-actin). Negative control (lines 3, 10 contain no template). The representative 
pictures of two independent experiments are shown. Primer pairs were kindly 
provided by Mark Moore. 
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Fig. 5.3. The expression of ST2L by freshly isolated and cultured human 
eosinophils (representative data). Peripheral blood human eosinophils were 
acquired as described in Materials and Methods section and FACS analyzed 
ex-vivo or cultured in-vitro over 2 days prior the evaluation of ST2L expression. 
FACS staining for ST2L was done with FITC-conjugated monoclonal antibody 
(MD Bioscience). Dead cell were excluded by staining with ViaProbe. Medium 
alone mildly increased ST2L expression while IL-5 downregulated 
medium-induced ST2L. IL-33 was able to induce ST2L and to reverse the 
IL-5-mediated negative regulatory effect. Representative data of six 
independent experiments is shown. 
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Fig. 5.4. The percentage of ST2L-expressing cells in fresh or cultured human 
eosinophils (quantitative data). Peripheral blood human eosinophils were 
acquired as described in Materials and Methods section and FACS analyzed or 
cultured in-vitro over 2 days prior ST2L expression evaluation. FACS staining for 
ST2L was done with FITC-conjugated monoclonal antibody (MD Bioscience). 
Data are means ± SEM (n = 6); #p < 0.05, IL-5 versus medium; *p < 0.05, 
medium versus IL-33 or IL-5 + IL-33  
.
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Fig. 5.5. The purity of murine bone marrow-derived eosinophils differentiated 
in vitro. After 48 hours of incubation in the presence of IL-5 bone marrow cells 
were sorted with FACS for CCR3highSiglec-F+ cells (typically, the purity was > 
98%). 
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Fig. 5.6. IL-33 but not IL-5 induces ST2L expression on murine eosinophils. 
Mature murine FACS-sorted WT eosinophils (Siglec-F+CCR3high) were cultured in 
medium with IL-5 (2ng/ml, control) or IL-5 (2ng/ml) + IL-33 (10ng/ml) over 2 
days. Data are representative of two independent experiments. Both control 
medium and IL-33 variant also contain the same concentration of IL-5 
(2ng/ml). 
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Fig. 5.7. IL-33 further increases the intensity of ST2L expression induced by 
GM-CSF. Mature murine FACS-sorted WT eosinophils (Siglec-F+CCR3high) were 
cultured in medium with IL-5 (2ng/ml, control) or IL-5 + GM-CSF (10ng/ml) or 
IL-5 + GM-CSF (10ng/ml) + IL-33 (10ng/ml) over 2 days. Data are 
representative of two independent experiments. 
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Fig. 5.8. IL-4 does not induce ST2L expression on murine eosinophils. Mature 
FACS-sorted WT eosinophils (Siglec-F+CCR3high) were cultured in medium 
+ IL-5 (2ng/ml, control) or IL-5 (2ng/ml) + IL-4 (10ng/ml) for 2 days. Data are 
representative of two independent experiments. 
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Fig. 5.9. ST2-/- eosinophils do not express ST2L. Mature murine FACS-sorted 
ST2-/- eosinophils (Siglec-F+CCR3high) were cultured in medium with IL-5 
(2ng/ml, control) or IL-5 + GM-CSF (10ng/ml) or IL-5 + GM-CSF (10ng/ml) 
+ IL-33 (10ng/ml) for 2 days. Data are representative of two independent 
experiments. 
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Fig. 5.10. Airway eosinophils express ST2L during OVA-induced airway 
inflammation model. WT and ST2-/- mice were sensitized with OVA + alum and 
subsequently challenged with OVA. BAL cells were collected 48, 72, 96 and 
120h after the last OVA challenge and stained with anti F4/80 Ab, anti-CCR3 
and anti-ST2L Abs. At 48h time point, up to 80% of BAL eosinophils 
(F4/80−CCR3+ cells) were ST2L+. Pooled data from 10 mice at each time point 
shown. 
 135 
 
 
 
 
 
 
 
 
 
Fig. 5.11. IL-33 triggers IL-13 production by murine eosinophils in vitro. 
FACS-sorted WT and ST2-/- eosinophils (Siglec-F+CCR3high) were incubated for 
48h in medium containing GM-CSF (1ng/ml, control medium) with or without 
IL-33. IL-13 concentrations in culture supernatants were analyzed by Luminex. 
Data are means ± SEM and are representative of three independent 
experiments. *p < 0.05, IL-33 versus control medium. 
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Fig. 5.12. IL-33 triggers IL-6 production by murine eosinophils in vitro. 
FACS-sorted WT and ST2-/- eosinophils (Siglec-F+CCR3high) were incubated for 
48h in medium containing GM-CSF (1ng/ml, control medium) with or without 
IL-33. IL-6 concentrations in culture supernatants were analyzed by Luminex. 
Data are means ± SEM and are representative of three independent 
experiments. *p < 0.05, IL-33 versus control medium. 
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Fig. 5.13. IL-33 enhances TARC (CCL17) production by murine eosinophil 
in vitro. FACS-sorted WT and ST2-/- eosinophils (Siglec-F+CCR3high) were 
incubated for 48h in medium containing GM-CSF (1ng/ml, control medium) with 
or without IL-33. CCL17 (TARC) concentrations in culture supernatants were 
analyzed by ELISA. Data are means ± SEM and are representative of three 
independent experiments. *p < 0.05, IL-33 versus control medium. 
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Fig. 5.14. IL-33 enhances TGF-β production by murine eosinophil in vitro. 
FACS-sorted WT or ST2-/- eosinophils (Siglec-F+CCR3high) were incubated for 
48h in medium containing GM-CSF (1ng/ml, control medium) with or without 
IL-33. TGF-β concentrations in culture supernatants were analyzed by ELISA. 
Data are means ± SEM and are representative of three independent 
experiments. *p < 0.05, IL-33 versus control medium. 
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Fig. 5.15. IL-33 enhances IgG-induced degranulation of mouse eosinophils 
in vitro. FACS-sorted mature eosinophils (Siglec-F+CCR3high) were pre-incubated 
with GM-CSF or GM-CSF + IL-33 for 24h before washed with fresh RPMI 
medium and seeded into 96-well plates for degranulation assay. After 
90 minutes EPO contents in supernatants was evaluated. Cell viability was 
assessed by counting in trypan blue. Total EPO release was calculated as the 
percentage of total EPO released from eosinophils that underwent 
3 freeze-thaw cycles. The amount of EPO released from dead cells was 
subtracted from the values shown. Data are means (3 technical 
replicates) ± SEM and are representative of three independent experiments. 
*p < 0.05, IgG1 (1µg/ml) + IL-33 (50ng/ml) versus IgG1 alone (1µg/ml). 
* 
% of total EPO release 
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Fig. 5.16. IL-33 enhances αCD32/16-antibody-induced degranulation of mouse 
eosinophils in vitro. FACS-sorted mature eosinophils (Siglec-F+CCR3high) were 
pre-incubated with GM-CSF or GM-CSF + IL-33 for 24h before washed with 
fresh RPMI medium and seeded into 96-well plates for degranulation assay. 
After 90 minutes EPO contents in supernatants was evaluated. Cell viability was 
assessed by counting in trypan blue. Total EPO release was calculated as the 
percentage of total EPO released from eosinophils that underwent 
3 freeze-thaw cycles. The amount of EPO released from dead cells was 
subtracted from the values shown. Data are means (3 technical 
replicates) ± SEM and are representative of three independent experiments. 
*p < 0.05; anti-CD32/16 antibody (1µg/ml) + IL-33 (50ng/ml) versus 
anti-CD32/16 antibody alone (1µg/ml). 
* 
% of total EPO release 
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Fig. 5.17. IL-33 enhances αCD32-antibody-induced degranulation of human 
eosinophils in vitro. Mature eosinophils purified from peripheral blood were 
pre-incubated with GM-CSF or GM-CSF + IL-33 for 24h before washed with 
fresh RPMI medium and seeded into 96-well plates for degranulation assay. 
After 90 minutes EPO contents in supernatants was evaluated. Cell viability was 
assessed by counting in trypan blue. Total EPO release was calculated as the 
percentage of total EPO released from eosinophils that underwent 
3 freeze-thaw cycles. The amount of EPO released from dead cells was 
subtracted from the values shown. Data are means ± SEM and are 
representative of three independent experiments. *p < 0.05; anti-CD32 
antibody (0.5µg/ml) + IL-33 (50ng/ml) versus anti-CD32 antibody alone. 
* 
* 
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Fig. 5.18. IL-33 enchances CD32 (FcγII receptor) but not CD16 (FcγIIIR) 
expression by human eosinophils in vitro. Peripheral blood eosinophils were 
enriched according to MACS Miltenyi protocol, pre-incubated with GM-CSF 
(1ng/ml) + IL-33 (10ng/ml) or with GM-CSF (1ng/ml) alone (control medium) 
over 24 h and CD32 and CD16 expression was evaluated by FACS. Data are 
representative of three independent experiments. 
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Fig. 5.19. IL-33-activated eosinophils increase the differentiation of 
alternatively activated MR+ but not TLR2+ macrophages in vitro. Murine 
macrophages from ST2-/- mice were cultured alone or co-cultured with 
FACS-sorted WT eosinophils (Siglec-F+CCR3high) in the presence of IL-5 
(5ng/ml) or IL-33 (10ng/ml). After 48h macrophages were stained with 
anti-TLR2 and anti-mannose receptor (MR) antibodies. Data are representative 
of three independent experiments. eos = eosinophil; mac = macrophage. 
Isotype 
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Fig. 5.20. IL-33-activated eosinophils increase the percentage of MR+ 
alternatively activated macrophages in vitro. Murine macrophages from ST2-/- 
mice were cultured alone or co-cultured with FACS-sorted WT eosinophils 
(Siglec-F+CCR3high) in the presence of IL-5 (5ng/ml) or IL-33 (10ng/ml). After 
48h macrophages were stained with anti-TLR2 and anti-mannose receptor 
(MR) antibodies. Data are means ± SEM of three independent experiments 
(n = 3), *p < 0.05, eosinophils + macrophages + IL-33 versus other cultures; 
eos = eosinophil; mac = macrophage. 
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Fig. 5.21. The IL-33-triggered macrophage switching to AAM phenotype is 
dependent on IL-13 (representative FACS results). Murine macrophages from 
ST2-/- mice were co-cultured with FACS-sorted WT eosinophils 
(Siglec-F+CCR3high) in the presence of IL-33 (10ng/ml) or IL-33 
(10ng/ml) + anti-IL-13 Ab or isotype control (10µg/ml). After 48h macrophages 
were stained with anti-TLR2 and anti-mannose receptor (MR) antibodies. The 
IL-33-induced increase in MR+ macrophages markedly blocked by anti-IL-13 Ab. 
Data are representative of three independent experiments. Eos = eosinophil; 
Mac = macrophage. 
Isotype 
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Fig. 5.22. The IL-33-triggered macrophage switching to AAM phenotype is 
dependent on IL-13 (quantitative data). Murine macrophages from ST2-/- mice 
were co-cultured with FACS-sorted WT eosinophils (Siglec-F+CCR3high) in the 
presence of IL-33 (10ng/ml) or IL-33 (10ng/ml) + anti-IL-13 Ab or isotype 
control (10µg/ml). After 48h macrophages were stained with anti-TLR2 and 
anti-mannose receptor (MR) antibodies. Data are means ± SEM of three 
independent experiments (n = 3), #p < 0.05, eosinophils + anti-IL-13 versus 
eosinophils + IgG. Eos = eosinophil. 
 147 
 
 
 
 
 
 
 
Fig. 5.23. IL-33 increases CD69 expression on human eosinophils 
(representative FACS results). PB eosinophils were cultured in complete 
medium or in medium complemented with IL-5 (10ng/ml) or IL-33 (10 or 
50ng/ml) for 48hours, followed by surface FACS staining for CD69 and ST2L. 
Results representative of 6 donors of 3 independent experiments are shown. 
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Fig. 5.24. IL-33 increases CD69 expression on human eosinophils (quantitative 
data). Human eosinophils were cultured in complete medium or in medium 
complemented with IL-5 (10ng/ml) or IL-33 (10 or 50ng/ml) for 48h, followed 
by surface FACS staining for CD69. Data are means ± SEM of 6 donors. 
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Chapter 6: 
The role of IL-33-activated eosinophils 
 in airway inflammation 
 150 
6.1. The contribution of IL-33-activated eosinophils to 
airway inflammation 
Given the role of the IL-33/ST2L system in eosinophil activation in vitro, I next 
investigated the contribution of IL-33-activated eosinophils to airway 
inflammation. FACS-sorted WT eosinophils (CCR3high Siglec-F+) were stained 
with CFSE and adoptively transferred i.n. into ST2-/- mice. Subsequently, 
recipients received IL-33 or PBS i.n. for 3 consecutive days. Mice were culled 
24h after the last IL-33 challenge and BAL fluid and cells were analyzed. 
Differential cell counts confirmed the presence of eosinophils in mice that 
received cells and a complete lack of eosinophils in the control groups given 
IL-33 or PBS only (Fig. 6.1.). Mice that received eosinophils plus IL-33 
exhibited markedly higher total cell, eosinophil, macrophage and lymphocyte 
counts than those that received eosinophils plus PBS. BAL from the recipients of 
eosinophils plus IL-33 also contained significantly higher numbers of host 
eosinophils (CFSE-) than the group given eosinophils plus PBS (Figure 6.1.). 
Moreover, IL-33-activated eosinophils increased CD4 T cell infiltration of the 
recipients’ lungs as measured by FACS (Figure 6.2.). These data indicate that 
adoptively transferred eosinophils stimulated with IL-33 have a potential to 
exacerbate airway inflammation. 
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6.2. The contribution of IL-33-activated eosinophils to airway 
cytokine expression levels 
Data presented in the section above suggest that IL-33, given to 
IL-33-unresponsive (ST2-/-) recipients, that had received WT eosinophils, 
induced the production of mediators that were likely responsible for attracting 
recipients’ inflammatory cells into the lungs. To further test this hypothesis 
I checked BAL fluids for the presence of cytokines and chemokines. BAL fluid 
analysis showed that, in contrast to animals that received PBS and IL-33 alone, 
both recipient groups that received eosinophils showed the presence of TARC 
(CCL17), MIP-1α (CCL3), eotaxin (CCL11), eotaxin-2 (CCL24), IL-13 and TGF-β 
(Figure 6.3.). However, mice that received eosinophils plus IL-33 produced 
significantly more CCL17, IL-13, TGF-β, CCL3 and CCL24 than those given 
eosinophils with PBS (Figure 6.3.). These data suggest that IL-33-activated 
eosinophils can indeed be a potent source of inflammatory mediators in the 
airways. 
 
6.3. The effect of IL-33-activated eosinophils on the 
phenotype of alveolar macrophages 
In section 5.3.3. I showed that IL-33-activated eosinophils were able to induce 
differentiation of BM derived macrophages into M2, AAM in co-cultures in vitro. 
Having found an increased number of macrophages in BAL from mice that 
received eosinophils plus IL-33 I was interested in the actual phenotype of 
 152 
these alveolar macrophages. To investigate this I stained BAL cells for F4/80, 
CCR3, MR, and TLR2. Alveolar macrophages from control mice had low 
expression of MR (a marker of M2 macrophage) that was consistent with their 
quiescent phenotype (26). The presence of adoptively transferred eosinophils in 
the airways increased the percentage of F4/80+CCR3- MR+ macrophages. 
However, mice that received eosinophils + IL-33 had a significantly higher 
proportion of MR+ macrophages than mice that received eosinophils + PBS 
(Figure 6.4.). The percent of TLR2+ (a marker of M1) macrophages was low 
and there was no difference between the groups (Figure 6.5.). These data 
therefore indicate that IL-33-activated eosinophils can increase the 
differentiation of alveolar macrophages toward the M2 phenotype in vivo. 
Summary of Chapter 6 
In summary, data presented in this chapter demonstrate that IL-33-activated 
eosinophils can significantly contribute to airway inflammation by releasing 
cytokines/chemokines, attracting other inflammatory cells and supporting the 
differentiation of alveolar macrophages towards M2, AAM. 
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Fig. 6.1. Adoptive transfer of IL-33-activated eosinophils results in the 
infiltration of the airways by ST2-/- recipients’ inflammatory cells. FACS-sorted 
WT eosinophils (Siglec-F+ CCR3high, 10x106/mouse) were stained with CFSE and 
adoptively transferred i.n. into ST2-/- recipients that were subsequently 
administered IL-33 for 3 days i.n. Control groups received eosinophils +PBS, 
PBS alone or IL-33 alone. Mice were culled 24 h after the last IL-33 
administration. BAL fluid differential cell counts are shown. Data are 
means ± SEM (n = 5 mice/group) and are representative of two independent 
experiments; *p < 0.05, eosinophils versus PBS or IL-33 alone #p < 0.05, 
eosinophils + IL-33 versus eosinophils + PBS. Eos = eosinophils; Recipients’ Eos 
= CFSE-negative eosinophils. 
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Fig. 6.2. IL-33 activated eosinophils attract CD4 T cells. FACS-sorted WT 
eosinophils (Siglec-F+CCR3high) were stained with CFSE and adoptively 
transferred i.n. into ST2-/- recipients that were subsequently administered IL-33 
or PBS daily for 3 days i.n. Mice were culled 24h following the last IL-33 
aministration. FACS staining for CD4 is shown. Data are representative of 5 
mice with similar results. Eos = eosinophil. 
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Fig. 6.3. Adoptively transferred IL-33-activated eosinophils induce 
inflammatory cytokine and chemokine production in the lungs of ST2-/- recipient 
mice. FACS-sorted WT eosinophils (Siglec-F+CCR3high) were adoptively 
transferred i.n. into ST2-/- recipients that were subsequently administered IL-33 
for 3 days i.n. Control groups received eosinophils +PBS, PBS alone or IL-33 
alone. Mice were culled 24h after the last IL-33 administration. Cytokine and 
chemokine concentrations measured in BAL fluid by ELISA are shown. Data are 
means ± SEM (n = 5 mice/group) and are representative of two independent 
experiments; *p < 0.05, eosinophils versus PBS or IL-33 alone; 
#p < 0.05,  eosinophils + IL-33  versus eosinophils + PBS; Eos = eosinophils 
TARC 
MIP-1α (CCL3)    eotaxin (CCL11)    eotaxin-2 (CCL24) 
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Fig. 6.4. Adoptively transferred IL-33-activated eosinophils markedly increase 
the proportion of alternatively activated macrophages (M2, AAM) in the lungs of 
ST2-/- recipient mice. FACS-sorted WT eosinophils (Siglec-F+CCR3high) were 
stained with CFSE and adoptively transferred i.n. into ST2-/- recipients that were 
subsequently administered IL-33 for 3 days i.n. Control groups received 
eosinophils +PBS, PBS alone or IL-33 alone. Mice were culled 24h after the last 
IL-33 administration. MR expression on BAL fluid macrophages (F4/80+CCR3-) is 
shown. Data are means ± SEM (n = 5 mice/group) and are representative of 
two independent experiments; *p < 0.05, eosinophils versus PBS or IL-33 
alone; #p < 0.05, eosinophils + IL-33 versus eosinophils + PBS; Eos = 
eosinophils. 
Macrophages 
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Fig. 6.5. IL-33-activated eosinophils do not alter the proportion of classically 
activated macrophages (M1) in the lungs of ST2-/- recipient mice. FACS-sorted 
WT eosinophils (Siglec-F+CCR3high) were adoptively transferred i.n. into ST2-/- 
recipients that were subsequently administered IL-33 for 3 days i.n. Control 
groups received eosinophils +PBS, PBS alone or IL-33 alone. Mice were culled 
24h after the last IL-33 administration. TLR2 expression on BAL fluid 
macrophages (F4/80+CCR3-) is shown. Data are means ± SEM 
(n = 5 mice/group) and are representative of two independent experiments; 
Eos = eosinophils. 
Macrophages 
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Chapter 7: 
Discussion 
 159 
Latterly, IL-33 has been implicated in type 2 lung inflammation mainly for its 
ability to affect T cell activation (80). However, the role of IL-33 in innate 
immune response in the lungs remains largely unknown. Studies in vivo showed 
that mast cells, basophils and NK cells are not essential for IL-33-induced 
airway inflammation ((185) and Pitman, N. et al., unpublished data).  
It was recently demonstrated that IL-33 can be released from naïve lung 
explants upon stimulation with LPS and alum, likely via NLRP3-mediated 
inflammasome activation (15). A study from our laboratory reported that IL-33 
protein is detected in the lungs of mice with OVA/alum-induced airway 
inflammation (43). Furthermore, immunohistochemistry studies carried out in 
our laboratory revealed that lung biopsies from asthma patients exhibit 
markedly elevated IL-33 expression in bronchial epithelial cells compared to 
healthy individuals, although a baseline IL-33 expression was observed in 
healthy controls as well. These data, in conjunction with recent reports 
suggesting that IL-33 can be rapidly released from epithelial cells in response to 
tissue injury or infection (6) seem to imply that IL-33 may play an important 
role in the pathogenesis of asthma, through the activation of lung resident cells 
that are readily expressing IL-33R, such as epithelial cells, fibroblasts and 
alveolar macrophages.  
Indeed, the latest study into the role of IL-33 in airway inflammation carried out 
in our laboratory (26) confirmed early reports (4, 48) that IL-33 induces 
massive airway inflammation manifested by eosinophil and macrophage 
infiltration of the lung tissue and BAL fluid, as well as markedly elevated local 
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concentrations of IL-5 and IL-13 and induced goblet cell hyperplasia. Most 
intriguingly, our study revealed a significant alteration to the quiescent 
phenotype of alveolar macrophages from IL-33 treated mice which exhibited a 
profound increase in the expression of mannose receptor and IL-4Rα, as well as 
produced Eotaxin-2 and TARC which together constitute the characteristics of 
alternatively activated macrophages (M2, AAM). Moreover, we demonstrated 
previously that the differentiation of AAM was IL-33/ST2 dependent and also 
required IL-13/IL-4Rα but not IL-4 (26). AAM contributed to the IL-33-induced 
innate type 2 inflammation in the lungs by releasing chemokines, particularly 
Eotaxin-2 which neutralization reduced IL-33 triggered airway inflammation 
(26). 
In order to confirm the role that alternatively activated alveolar macrophages 
play in IL-33-induced airway inflammation I employed a technique designed by 
Thepen et al. (157) which allows for the depletion of alveolar macrophages 
in vivo by means of intranasal administration of clodronate-containing 
liposomes that specifically target alveolar macrophages (Figure 2.2.). I was 
able to show that elimination of macrophages from the alveolar space leads to 
the amelioration of the IL-33-induced inflammation as reflected by decreased 
total BAL cell counts, as well as eosinophil counts in clodronate treated mice 
compared to PBS control (Figure 3.2.). Furthermore, I provided an insight into 
the mechanism by which IL-33 induces the differentiation of of alveolar 
macrophages toward AAM and thus inducing airway inflammation by 
demonstrating that IL-13 signaling pathway plays an essential role in this 
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process and its disruption significantly ameliorates IL-33-induced airway 
inflammation (Figure 3.3.). 
By releasing chemokines, in particular eotaxin-2 (CCL24) (26), alveolar 
macrophages constitute a link between lung resident cells that act as the first 
line of response to IL-33 and several other cell types of the immune system, 
such as eosinophils, basophils mast cells and T cells, all of which can be 
recruited into the lungs and contribute to the IL-33-induced airway 
inflammation. 
Given the prominent role of eosinophil leukocyte in asthma pathogenesis (186), 
in conjunction with more recent studies demonstrating that human eosinophils 
are able to express IL-33R (ST2L) in vitro (187), the contribution of IL-33/ST2 
pathway to eosinophil differentiation and activation during the course of airway 
inflammation required further clarification. 
Enhanced eosinophil differentiation is a hallmark feature of most clinical and 
experimental asthma phenotypes (143, 188) as well as IL-33-induced airway 
inflammation as demonstrated here and elsewhere (4, 48). Data obtained 
during this project indicate that IL-33 can act directly on bone marrow 
CD117+ST2L+ hematopoietic precursor cells and induce their differentiation 
toward eosinophils. This process depends on IL-5 and is IL-9 and IL-13 
independent. Thus, IL-33-driven eosinophilia is likely a consequence of the 
cooperative autocrine action of IL-5 produced by CD117+ hematopoietic 
precursors themselves that leads to their differentiation to eosinophils in bone 
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marrow, and the effect of IL-5 and/or chemokines produced by the cells on the 
periphery (4, 26, 29, 43) that mobilize mature eosinophils from the bone 
marrow compartment to the inflamed tissue. Further studies are needed to 
identify which progenitor cell population responds to IL-33 as both CMP and 
GMP express CD117 (90) (see Figure 1.3.). 
Consistent with the above findings, recent study demonstrated that human 
hematopoietic CD34+ cells from asthma patients express ST2L and respond to 
IL-33 by IL-5 production (189). This raises a possibility that IL-33 may drive 
eosinophil differentiation from hematopoietic precursors in clinical settings.  
Furthermore, I show here that IL-33/ST2 system is essential for an optimal 
expression of CCR3 by differentiating eosinophils. It is well documented that 
CCR3 is of particular importance for eosinophil biology as it combines its action 
with IL-5 to facilitate mobilization of eosinophils from bone marrow to 
peripheral blood and it is ultimately responsible for eosinophil trafficking into 
the sites of inflammation (190). The lack of an optimal expression of CCR3 on 
ST2-/- eosinophils can likely be responsible for a decreased number of recruited 
eosinophils in BAL of ST2-/- compared to WT mice during OVA-induced airway 
inflammation model (Figure 5.10.), (26, 43). Of note, and in agreement with 
recent studies (191), IL-33 did not affect CCR3 expression on eosinophils that 
are already in the periphery (data not shown) or at sites of inflammation. 
The accumulation of eosinophils in the airways is a prominent feature of most 
clinical asthma subtypes and experimental asthma models (143, 188). Many 
 163 
human and animal studies point out the important function of eosinophils in the 
exacerbation of lung disease and airway remodeling (143). However, the 
precise factors that are responsible for the localized activation of eosinophils in 
the asthmatic lungs are not fully recognized. This become of particular 
importance in the light of recent finding that airway eosinophils are not 
susceptible to IL-5 as they shed their surface IL-5 receptor while they enter 
airway lumen (166). Given the abundant expression of IL-33 in the stromal 
tissue of asthmatic lungs (26-27), the possibility arises that IL-33 may trigger 
the activation of eosinophils that have been recruited to the airways. 
Consistent with data published previously (191-192), I found that only limited 
proportion of mature mouse and PB eosinophils of most human donors 
expressed ST2L although they did express mRNA for both ST2L and sST2. By 
contrast, eosinophils that accumulated in airways during OVA-induced asthma 
model did express high levels of ST2L on the surface. My in vitro studies 
revealed that both IL-33 itself and GM-CSF are likely to upregulate ST2L on 
airway eosinophils. Intriguingly, IL-5 seems to play an inhibitory role in ST2L 
expression if acting alone on human eosinophils. This might prevent the 
activation of eosinophils driven by constitutive low levels of IL-5, GM-CSF and 
IL-3, which may be present under normal steady-state conditions. 
The observation that in two out of six human donors PB eosinophils exhibited 
readily detectable ST2L expression could be attributed to the mild ongoing 
allergic reactions in those subjects. However, further studies in a bigger 
population of clinically diagnosed allergic individuals and healthy subjects are 
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required in order to establish a true variation of ST2L expression in human PB 
eosinophis. 
Recent studies on eosinophil deficient mice show an important role of 
eosinophils in cytokine and chemokine production, and thereby their 
contribution to the perpetuation of inflammation (110, 145). Here, I show that 
IL-33 can be a trigger of these processes. IL-33/ST2-activated eosinophils 
contribute to the exacerbation of inflammation by increasing the number of 
macrophages and lymphocytes in the lungs which can be attributed to the 
increase in levels of cytokines and chemokines, including TARC, IL-13, TGF-β, 
MIP-1α and Eotaxin-2. My in vitro data show that murine eosinophils can be a 
potent source of TARC, IL-13, IL-6 and TGF-β upon IL-33 stimulation. 
Interestingly, pulmonary, eosinophil-dependent TARC release appears to be 
required for the localized recruitment of effector T cells during asthma model 
(145). I was able to demonstrate that IL-33 can be a factor that drives TARC 
production by eosinophils and this is followed by the accumulation of CD4 cells 
in the airways. 
IL-33 in vitro seemed to have no effect on eotaxin-2 and MIP-1α production by 
eosinophils themselves. Thus, elevated levels of these two chemokines found in 
BAL of ST2-/- recipients that received WT eosinophil cells followed by IL-33 
injection are probably due to an indirect effect of IL-33-stimulated eosinophils 
interacting with other cell population in the lungs, such as alveolar 
macrophages. In fact, the very presence of eosinophils in the airways triggers 
the differentiation of quiescent alveolar macrophages towards MR+ alternatively 
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activated macrophages, a phenotype that is pathogenic in type 2 diseases (26, 
150). Studies focused on a mechanism behind this process revealed that IL-13, 
which is a well known AAM differentiation factor that is also released by 
eosinophils upon IL-33 stimulation can be, at least partially, responsible for the 
increased differentiation of AAM macrophages. Consistent with our data, Rankin 
et al. demonstrated that IL-33 induces the production of IL-13 from eosinophils 
which, in turn, can promote the development of cutaneous fibrosis (193). 
Moreover, the elegant studies by Pope et al. and Kurowska-Stolarska et al. 
suggest that BAL AAM macrophages may be the major producers of Eotaxin-2 
in experimental asthma model (26, 127). Thus, it is likely that AAM are 
responsible for the elevated levels of Eotaxin-2 that I could observed in 
recipients given eosinophils plus IL-33.  
There is growing evidence to support the notion that eosinophils also have the 
capacity to regulate mast cell function, which are producers of an array of 
chemokines, including MIP-1α (130, 194). Therefore; lung resident mast cells 
may likely release MIP-1α upon interaction with IL-33-activated eosinophils.  
Furthermore, IL-33-activated WT eosinophils, consistent with the BAL 
chemokine profile they contribute to, could attract more host (ST2-/-) 
eosinophils to the airways. Intriguingly, administration of IL-33 locally into the 
lungs also helped maintain significant numbers of adoptively transferred 
eosinophils in the airways. This may be explained by the effect of IL-33-induced 
chemokines that lock those cells in the airways. Furthermore, the survival of 
adoptively transferred eosinophils may be enhanced either as a result of an 
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interaction with other cells or as a direct effect of IL-33. The latter possibility is 
supported by observations in human eosinophils in vitro (187, 191-192). 
Finally, my work provides evidence that IL-33 can significantly increase the 
eosinophil susceptibility to antibody-triggered degranulation by increasing the 
expression the expression of FcγΙΙR (CD32). Thus, the release of IL-33 from 
inflamed tissue may be a crucial factor responsible for cytotoxic 
granule-mediated tissue damage in clinical settings. In contrast to other studies 
(187), I did not detect any substantial eosinophil degranulation in the presence 
of IL-33 or IL-5 alone. In support of my findings, numerous studies suggest 
that cytokines, such as IL-5 for example, also have a limited contribution to the 
degranulation process, compared to potent degranulation factors such as 
immuno-complexes or complement molecules (195-196). 
Taken together, IL-33/ST2 pathway regulates multiple features of eosinophil 
biology that can have a significant impact on allergic inflammation and asthma. 
In this project, I show that IL-33 can directly differentiate eosinophils from 
bone marrow precursors. Most importantly, I demonstrate that mature 
eosinophils can acquire high levels of IL-33 receptor (ST2L) at sites of airway 
inflammation. Finally my work provides new evidence that eosinophils activated 
through the IL-33/ST2 signaling pathway play an important role in airway 
inflammation in vivo. A possible mechanism by which IL-33 activates 
eosinophils and their contribution to airway inflammation is summarized in 
Figure 7.1.  
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Given the limited benefit of anti-IL-5 therapy in asthma patients, reflected by 
only moderate decrease in sputum eosinophil counts (only 55% reduction) and 
lack of clinical benefit (197-198), inhibition of the IL-33/ST2 pathway can be 
considered a promising therapeutic target. This notion is supported by an 
increasing number of studies showing that IL-33/ST2 pathway is equally 
important in the activation of other cell types involved in the pathogenesis of 
allergy and asthma, such as Th2 cells, mast cells, DC and macrophages (4, 26, 
29, 43, 48, 68). 
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Figure 7.1. The contribution of IL-33-induced eosinophils to airway 
inflammation 
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